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SUMMARY
Prostate cancer is the second most commonly diagnosed cancer in the Western world and 
the second most common cause of male cancer-specific death. Most patients either 
present with extracapsular or advanced disease, or develop it following radical therapy for 
localised disease. The mainstay of treatment for advanced prostate cancer has not changed 
significantly for over 50 years and is based on androgen-deprivation therapy.
Hormonal or androgen-deprivation therapy aims to inhibit androgen production or action, 
thereby reducing stimulation of the androgen-receptor (AR). This in turn prevents the 
activation of androgen-regulated genes, which normally result in on-going growth, 
survival and inhibition of apoptosis. Initial response rates to androgen-deprivation therapy 
are high, however within an average of 18-24 months following commencement of 
treatment patients relapse with androgen-insensitive disease (AIPC). This indicates 
reactivation of androgen-dependent gene transcription, resulting in renewed tumour 
growth. Clinically, AIPC manifests itself in local tumom* progression, distant metastasis 
and, ultimately, death within 12-18 months. This remains a significant clinical problem as 
it contributes to the majority of the morbidity and mortality associated with advanced 
prostate cancer.
The progression to AIPC involves disruption to cell growth, differentiation and apoptosis 
despite on-going androgen suppression. These result from alterations to the androgen 
signalling pathway and other sub-cellular molecular pathways. The development of novel 
therapies to treat AIPC however has been hampered in the past by limited information 
regarding these underlying molecular causes. A profound understanding of the various 
molecular pathways involved is crucial as specific targets are needed for molecular-based
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cancer therapy. The use of patient material to define such targets is clearly required and 
although their exact nature is still poorly understood, interactions with growth factors and 
their receptors are clearly involved. Such potential targets include the type 1 receptor 
tyrosine kinases (EGFR and HER2) and their downstream pathways.
We hypothesised that the Raf/MAP Kinase cascade to be one such pathway, based on 
previous gene array data from our laboratory. This revealed amplification of members of 
the Raf/MAP Kinase pathway along with HER2 with the development of AIPC, which 
suggested that the Raf/MAP Kinase pathway promoted the development of clinical AIPC. 
The purpose of this M.D. was to further investigate the role of this signal cascade in AIPC 
by determining if these previously identified genetic changes had functional consequences 
in terms of protein expression. The role of the Raf/MAP Kinase pathway was investigated 
using clinical, archival material which consisted of paired, matched histological tissue 
specimens obtained before commencement of androgen deprivation therapy and after the 
development of androgen-escape. The expression levels and activation status of Raf-1 and 
MAP Kinase (2 critical members of the MAP kinase cascade) were determined in these 
matched ASPC and AIPC tumours using immunohistochemistry. Protein expression was 
then correlated with time to biochemical relapse, time to death from relapse and overall 
suivival. Correlations were also made with the type 1 tyrosine kinase receptors, EGFR 
and HER2 (known to activate the pathway), and the known downstream targets, AR and 
AP-1, in the same cohort of patients.
In doing so, increased protein expression of the pathway was seen to significantly impact 
on patient sui*vival. Patient tumour specimens which displayed a rise in Raf-1 expression 
had a significant reduction in time to biochemical relapse (p<0.0005). Furthermore, rising 
nuclear expression of MAP Kinase was strongly associated with shortened time to death
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from (p=0.0255) relapse resulting in reduced overall suivival (p=0068). Correlations also 
existed with other critical members of the pathway in vivo. Correlations were seen 
between type 1 receptor tyrosine kinases and members of the Raf/MAP Kinase pathway 
before and after the development of AIPC, whilst further significant correlations 
developed with the c-fos and c-jun (components of the transcription factor AP-1) with the 
development of AIPC.
From this data, the following can be concluded. Raf-1 and MAP Kinase appear to be 
involved in the development of AIPC, as their expression significantly impacts on known 
clinical parameters -  namely, time to biochemical relapse and overall survival. This 
indicates a potential prognostic role for the MAP Kinase cascade in AIPC. In addition, 
positive correlations with other proteins may indicate that a type 1-tyrosine kinase 
receptor/Raf-MAP Kinase /AP-1 axis forms a functional pathway which plays a role in 
the development of clinical AIPC. This would imply that members of the Raf/MAP 
Kinase pathway may act as a therapeutic target in selected patients.
The data provides, for the first time, clinical evidence to support our hypothesis that the 
Raf/MAP Kinase pathway is utilised in AIPC and plays a role in promoting its’ 
development and progression. Further analysis of this pathway, and its’ role in AIPC 
using clinical material, are clearly warranted. These findings lead us to hypothesise 
further that expression of Raf-1 and MAP Kinase would yield useful predictive 
information for patients at risk of AIPC and that targeting of the type 1-tyrosine kinase 
receptor/Raf-MAP Kinase /AP-1 axis in this sub-group of patients may yield a novel and 
exciting therapeutic avenue in the future.
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INTRODUCTION
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1.1 Prostate Cancer -  Background
1.1.1 Incidence and Natural History
Prostate cancer is the second most commonly diagnosed cancer in the Western world. 
Prostate cancer incidence in the United Kingdom is approximately 25,000 cases per year 
and is the second most common cause of male cancer-specific death (2003) (Trachtenberg 
and Blackledge, 2002) (Debes and Tindall, 2004). At diagnosis, localised or organ- 
confined disease may be treated and potentially cured with radical surgery or radiotherapy. 
However many patients present with extracapsular or advanced disease (be it locally or 
regionally advanced or metastatic disease), the management of which has not significantly 
changed for over 50 years (Linja et al., 2001). Furthermore, approximately a third of 
patients who undergo radical therapy for localised disease will eventually relapse with 
advanced disease. The mainstay of treatment for patients with advanced disease is based 
on androgen-deprivation therapy, and this approach has remained unchanged ever since 
Huggins and Hodges first demonstrated the hormonal dependence of prostate cancer in 
1941 (Huggins and Hodges, 2002). Their work revealed, for the first time, the growth 
suppressive effect of reducing endogenous androgen levels, by surgical castration, in 
patients with prostate cancer. Prostatic growth and development is dependent on androgen, 
in the form of testosterone and dihydrotestosterone. Hormonal or androgen-deprivation 
therapy aims to inliibit androgen production or action, thereby reducing stimulation of the 
androgen-receptor (AR). This in turn prevents the activation of androgen-regulated genes, 
which normally result in on-going growth, survival and inhibition of apoptosis. Initially 
this is effective in reducing tumour growth in 70% - 80% of men (androgen sensitive 
prostate cancer or ASPC), however all patients eventually develop resistance to therapy 
and relapse with androgen insensitive prostate cancer (AIPC) for which there are only 
limited, palliative treatment options.
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The development of androgen escape remains a significant clinical problem, as it leads to 
disease progression and metastasis. This in tinn contributes to the majority of the 
morbidity and mortality associated with prostate cancer (Sciarra et al., 1999) (Dorkin and 
Neal, 1997). The development of novel therapies to treat or prevent the onset of AIPC has 
been hampered in the past by limited information regarding its’ underlying causes. Such 
treatments are, however, required urgently as the incidence of prostate cancer is forecast to 
increase by 20% within the next 10 to 25 years (Beemsterboer et al., 1999).
1.1.2 Current Challenges & Treatment Options
1.1.2.1 Current Challenges in Prostate Cancer
Various difficulties exist with regard to the understanding of the biological course of 
prostate cancer as well as its’ therapeutic management. The development of clinically 
progressive disease does not always occur within the lifetime of every patient with 
histological evidence of cancer (Culig et al., 2002). As a result, while some patients have 
a high risk of dying of prostate cancer, the remainder live with microscopic but not 
clinical evidence of disease, eventually succumbing to death from other causes. The 
detection and diagnosis of prostate cancer as a result of screening is hindered a failure to 
differentiate effectively between these patients, thereby reducing mortality (Parker, 2003). 
One of the goals of current research is to develop new ways of identifying patients with 
clinically aggressive and life-tlireatening disease, and, thereafter, deciding what form of 
treatment should be administered - whether curative (by radical surgery or radiotherapy) 
or not.
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-Another controversy lies in the management of advanced or non organ-confined disease.
Androgen-deprivation therapy relies on the suppression of androgen production and/or
,function, thus preventing activation of AR-mediated signalling and gene transcription (see
.Figure 1). Inhibition of testicular androgen production may be achieved surgically
.(bilateral orchidectomy) or chemically, using gonadotropin-releasing hormone (GnRH) 
agonists. The latter induces castrate levels of testosterone by down-regulating pituitary 
GnRH receptors (and therefore gonadotropin hormone production) through constant 
stimulation. In addition, the action of androgen may be blocked at a peripheral level using 
androgens, which inhibit ligand binding to AR and subsequent activation. Androgens may 
be steroidal (cyproterone acetate) or non-steroidal (hydroxyflutamide or bicalutamide -  
which have the advantage of possessing no hormonal activity). Either form of therapy 
may he used alone in the treatment of locally advanced disease, however overall survival 
in localised, high grade or metastatic disease prostate cancer is improved only with 
medical or surgical castration (Wirth et al., 2004), Long-term adjuvant androgen- 
deprivation therapy has also been shown to increase local control and survival when used 
in conjunction with radical radiotherapy in locally advanced disease (Gottschalk and 
Roach, III, 2004) (Bolla et al., 2002).
Initial response rates to androgen-deprivation therapy are high, however within an average
of 18-24 months following commencement of treatment patients relapse with “androgen-
.escape” or androgen-insensitive/independent disease (AIPC). This indicates reactivation 
of androgen-dependent gene transcription, resulting in renewed tumour growth. 
Clinically, AIPC manifests itself in local tumour progression, distant metastasis and, 
ultimately, death within 12-18 months (Trachtenberg and Blackledge, 2002). Serum levels 
of the kallikrein, prostate-specific antigen (PSA) -  an androgen-regulated gene product
26
—
which acts as a biochemical indicator of disease progression and tumour load -  
subsequently rise (Gao et al., 1997) (Stamey et al., 1987). PSA is therefore used as a 
clinical marker of this event, as well as in the initial diagnosis of prostate cancer. The 
development of AIPC results in considerable patient morbidity and mortality, with 
features such as spinal cord compression, pathological fractures and hypercalcaemia 
(secondary to bone metastasis), as well as obstructive renal failure (secondary to bladder 
outlet obstruction).
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Figure 1. A ndrogen-A xis with Therapeutic Sites o f Action
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Currently, second-line strategies involving hormonal therapy have been explored in a bid 
to delay the progression o f (if  not prevent or cure) androgen-insensitive disease itself. 
Maximal androgen blockade (MAE) consisting o f both forms o f androgen-deprivation
therapies was first proposed over 20 years ago (Labrie et a l, 1985). The principal behind 
such an approach is to nullify the effects of the 10-30% of circulating androgen produced 
by the adrenal glands, which are not counteracted by GnRH analogue treatment alone. 
However its’ therapeutic benefit still remains unproven, with the majority of trials 
showing only a modest survival benefit at best. It has been suggested that this may be 
related to varying trial designs (including differing outcome measures) as well as differing 
efficacies between non-steroidal androgens themselves (Klotz, 2001). Despite this, it is 
thought that MAB has the potential disadvantages of increased drug toxicity, although this 
too remains under review (Pether and Goldenberg, 2004) (Damber, 2004). Interestingly, 
following the development of AIPC, withdrawal of androgen treatment has been shown to 
result in a temporary decline in PSA in up to a third of patients, with a subsequent clinical 
improvement (Kelly and Scher, 1993). The underlying molecular mechanisms behind this 
“androgen-withdrawal” phenomenon are not as yet clear, however they may also be 
related to the subsequent development of AIPC (Miyamoto et al., 2004). These 
mechanisms will be discussed in more detail in the next section.
Chemotherapy
As the proliferation rate of prostate cancer is comparatively low, with respect to other 
cancers, chemotherapy was initially thought to be of limited value in advanced stages of 
disease progression (Culig et al., 2002) (Zelivianski et al., 2003). Long-term therapy with 
adriamycin and taxol, for example, leads to resistance to apoptosis (Culig et al., 2002). 
Despite this, several clinical studies have sought to determine the potential role of 
chemotherapy in advanced AIPC (Culine and Droz, 2000). Whilst not curative, 
chemotherapy has been shown to give significant palliative benefit in symptomatic 
patients in terms of pain control and quality of life, especially in combination with
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corticosteroids. Moreover, recent trials with combination chemotherapy, in particular with 
the taxol-based chemotherapeutic agents paclitaxel and docetaxel, have yielded promising 
results with regards to PSA levels and survival benefits (Culine and Droz, 2000). 
Paclitaxel in combination with estramustine results in a PSA decrease of greater than 50% 
in 65% of patients, although with no overall survival benefit (Smith et al., 1999). A phase
II trial using docetaxel in combination with mitoxantrone resulted In a similar PSA 
response in 62% of patients (Heidenreich et al., 2003) and in 84% of patients when 
combined with estramustine (Petrylak et al., 1999). Following on from this, 2 recent phase
III trials have confirmed a modest survival benefit with docetaxel combined with 
estramustine (Petrylak et al., 2004) or prednisolone (Tannock et al., 2004) - the first time 
large-scale randomised trials have demonstrated a sui*vival benefit with any form of 
chemotherapy in AIPC. The molecular basis for taxol-based chemotherapy is well- 
characterised. Taxanes, like other chemotherapeutic agents such as estramustine, inhibit 
microtubule disassembly by binding to tubulin and arresting cells at the G2/M phase 
(Debes and Tindall, 2004). In addition, docetaxel can lead to phosphorylation of bcl-2, 
increasing free bax and activating apoptosis via the caspase cascade.
Despite these developments, any modest survival benefit of such chemotherapeutic 
regimes must be balanced with its’ toxicity, in particular neutropenia, which clearly 
impacts on and compromises the quality of life for patients who have a limited life 
expectancy in any case.
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Other Hormonal Treatments
The use of oral oestrogen (stilboestrol) therapy for medical castration has long been 
superseded due to cardiovascular mortality. Such effects may be circumvented however 
by parenteral oestrogen administration which has been shown to have equal efficacy as 
MAB in terms of survival and cardiovascular side-effect profile (Hedlund and 
Henriks son, 2000).
In contrast to analogues, GnRH antagonists (e.g. abarelix) bind to pituitary GnRH 
receptors, blocking GnRH release. A recent phase III trial comparing it with MAB 
(leuprolide and bicalutamide) revealed a more rapid reduction of testosterone to castration 
levels with no androgen flare. However, no actual improvement in survival has been 
demonstrated and as a result there remains a significant question regarding its’ cost- 
benefit ratio.
Therefore, current treatments for AIPC are mainly palliative with no effective curative 
options for what is clearly a serious clinical problem. Prostate cancer is predominantly a 
disease of the elderly, however current demographic trends forecast a 60% rise in the 
male population over the age of 50 in the next 15 years, with a resulting 20% rise in the 
incidence of prostate cancer itself (Beemsterboer et al., 1999) (Boyle P, 4 A.D.). In 
addition, there is an increasing trend for patients to be diagnosed earlier through screening 
programmes. The risks of developing AIPC will therefore increase in younger patients as 
androgen-deprivation therapy is being increasingly used as adjuvant therapy with radical 
treatments. There are a lack of effective treatment options that improve survival and/or 
prevent complications due to disease progression. The clear challenge facing clinicians 
and scientists is therefore to develop novel therapies that improve survival, with minimal
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adverse effects that may compromise on patient quality of life. This will have a major 
impact on the provision of future healthcare resources.
1.1.3. Future M anagement
In order to develop effective novel therapeutic approaches for the future, it is crucial to 
understand the molecular mechanisms underlying the development of prostate cancer and 
AIPC. This has not been straightforward, with the failure to establish a reliable primary 
culture model to study androgen-responsiveness being one particular difficulty (Culig et 
al., 2002) (Linja et al., 2001).
Nevertheless, progress has been made recently. Prostatic cells are known to be regulated 
by androgens, with the testosterone-AR complex / axis playing a key role in determining 
the expression of genes controlling cellular growth, and differentiation, as well as 
apoptosis. In the last 10 to 15 years there has been a great deal of published research 
dealing with the crucial role of this AR signalling pathway in controlling normal cell 
development, as well as its’ role in prostate carcinogenesis. This has led to a greater 
understanding of its’ participation, and in particular its’ dysregulation, in the progression 
of the disease including the development of AIPC. The AR signalling pathway may well 
therefore contain potential therapeutic targets, and this possibility will be explored in the 
next section.
However, the microenvironment of prostate cells and the AR signalling pathway is also 
influenced by external regulatory factors such as growth factors and cytokines. Androgens 
and AR-signalling are a central component of this process, interacting with such 
regulatory factors. These factors may also be responsible for setting up paracrine and
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autocrine feedback loops leading to dysregulated and possibly androgen-independent 
growth via activation of downstream signal cascades, such as the p42/44 MAP kinase 
pathway. An imbalance between these finely balanced growth stimulatoiy and inliibitory 
mechanisms is thought to he the major factor driving the neoplastic process in general. It 
is therefore not surprising that the development of AIPC is associated with a significant 
increase in growth factor expression, which is believed to fuel androgen-independent 
growth (Culig et al., 1994). Preventing the activation of these pathways provides a 
possible new avenue for the treatment of AIPC and will also be discussed in a later 
section.
Long-term androgen-deprivation leads to recovery in growth and increased sensitivity to 
low doses of androgens. It has therefore been hypothesised that, whilst in the early phase 
of prostate carcinogenesis cells posses a degree of androgen-dependence, disease 
progression is marked by acquired resistance to treatment possibly due to genetic 
mutations. Such changes result in cells becoming susceptible to chronic autocrine 
stimulation from growth-promoting signalling pathways, independent of androgen- 
control. Increased or dysregulated oncogene activation resulting in the altered expression 
and function of growth factors, growth factor-receptors and loss of tumour suppressor 
gene products may therefore form the basis of AIPC development. An alternative theory 
however proposes that androgen-independent cells co-exist with androgen-dependent cell 
from the start, and subsequently undergo “selection pressure” during androgen- 
deprivation therapy (Miyamoto et ah, 2004) (Linja et ah, 2001) (Isaacs, 1999). This has 
led to the clonal selection theory of AIPC which results from intrinsic resistance. As a 
result, the use of intermittant androgen suppression - with cycles of hormone therapy 
given only during rises in PSA and withdrawn upon stabilisation -  is currently under
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evaluation as a means of delaying AIPC development (Pether and Goldenberg, 2004), 
This technique would theoretically allow androgen-sensitive cells to repopulate between 
cycles of therapy, whilst offering equal therapeutic efficacy and a reduction in the long­
term drug side-effects and therefore improvement in quality of life. The results of 
definitive, randomised trials are, however, awaited.
As a result of our cun-ent understanding at a molecular level, prostate cancer is now 
thought to be a heterogeneous disease, both histologically and biologically. This is due 
to complex molecular interactions between androgens, growth factors, receptor and 
intracellular proteins. A multi-disciplinary approach to its’ investigation encompassing 
endocrinology, biochemistry, molecular genetics and histopathology will therefore 
provide a better understanding of the disease. It seems likely that the use of combined 
conventional and molecular therapies will form the basis of future treatment of advanced 
prostate cancer (Culig et ah, 2002). The development of novel therapies may depend on 
the “molecular profiling” of patients i.e. matching specific targets with the individual. For 
such an approach to be successful, it will be essential to use patient material to validate 
such targets or pathways in terms of their actual function in clinical AIPC development. It 
is this premise that provides the basis of this thesis.
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1,2 The Molecular Basis of AIPC
1.2.1 The Androgen Receptor
I.2.I.I. Structure and signalling of the Androgen Receptor
The androgen receptor (AR) is a steroid receptor and a ligand-activated transcription 
factor. It is involved in the regulation of male sexual development, maintenance of libido, 
and the growth and functioning of accessory sexual organs such as the prostate gland 
(Culig et al., 2002) (Trachtenberg and Blackledge, 2002). At the molecular level it 
consists of 3 domains (Culig et ah, 2002) (Edwards and Bartlett, 2004) (Figure 2). The 
DNA-binding domain (DBD) contains a hinge-region and 2 zinc finger motifs that bind to 
specific androgen-responsive elements (AREs) of androgen-regulated genes. The hinge 
region contains specific sequences involved in receptor dimérisation and translocation to 
the nucleus (Lee and Chang, 2003). Phosphorylation at these sites may result in 
inactivation of the AR (Rochette-Egly, 2003). The C-Terminal or ligand-binding domain 
(LBD) is critical for the binding of hormone and the subsequent ligand-dependent 
activation of the AR. In addition, it is involved in the regulation of transcription via the 
activation function-2 (AF-2) region, and interacts with co-activators (following a 
conformational change triggered by ligand-binding) (Rochette-Egly, 2003). The N- 
Terminal domain (NTD) contains the activation function-1 (AF-1) region, which is also 
involved in the regulation of transcriptional activity, and is the target of multiple protein 
kinase pathways (Lee and Chang, 2003) (Ueda et ah, 2002b) (Edwards and Bartlett, 
2005). AF-1 contains numerous putative ligand-dependent and independent 
phosphorylation sites consisting of a variable number of polyglutamine or glycine repeat 
sequences. It also interacts with p i 60 co-regulatory proteins, independently of hormone- 
binding, allowing bridging with the AF-2 domain (Rochette-Egly, 2003). Inhibition of this 
communication by phosphorylation may reduce ligand-binding, inliibiting AR function
35
0  (Rochette-Egly, 2003). Phosphorylated NTD may also allow targeting o f the AR for
enzymatic degradation (Rochette-Egly, 2003).
Figure 2. Structure o f the AR
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The functional status o f the AR, in particular its’ transcription ability, is closely associated 
with its’ phosphorylation status (Grossmann et ah, 2001) as well as its’ homodimerisation 
ability (Culig et ah, 2002). While AR agonists and antagonists are known to differentially 
phosphorylate the AR, identifying which other cellular protein/regulatory kinases that also 
act on the AR, and their respective phosphorylation sites is crucial to unravelling the 
molecular details o f the AR-signalling pathway.
The primary ligand for the AR is dihydrotestosterone (DHT), which has a 10 times higher 
affinity than testosterone as a ligand (Suzuki et ah, 2003) (see Figure 3). Testosterone 
(produced by testicular Leydig cells) is converted to DHT by 5o:-reductase type 2 upon 
entry into prostatic epithelial cells. In the absence o f ligand, the AR is normally bound to 
several heat shock proteins (HSPs), which protect it from degradation, maintaining a 
dormant state and preventing activation (Culig et ah, 2002) (Edwards and Bartlett, 2005).
upon binding to ligand, a conformational change occurs allowing dissociation o f HSPs 
(Ueda et ah, 2002b), The AR is then phosphorylated, which stabilises the ligand-receptor 
complex, and forms a homodimer (Lee and Chang, 2003) (Edwards and Bartlett, 2005). 
The complex subsequently translocates from the cytoplasm to nucleus to act as a 
transcription factor (Wang et ah, 1999) but as such is exposed to protease degradation. 
The AR initiates gene transcription by binding to specific AREs (consensus nucleotide 
sequences that are specific for the AR in promoter regions o f target genes) (Lee and 
Chang, 2003). Upon binding, co-activators (eg SRC-1, CBP) also interact with the AR to 
enhance transcription by bridging various transcription factors to aid formation o f a stable 
and functional pre-initiation complex (Rochette-Egly, 2003). The formation o f this 
complex at the initiation site facilitates entry o f transcription machinery, such as RNA 
polymerase II, allowing commencement o f specific gene transcription (Rochette-Egly, 
2003;Suzuki et ah, 2003).
Figure 3. Interaction Between Androgen and the AR Pathway
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1.2.1.2. Genetic Modifications of the AR in AIPC
Downregulation of the AR-signalling pathway with hormone therapy could potentially 
explain the development of AIPC on a molecular level. Using immunohistochemical 
studies, however, the AR has been consistently demonstrated in prostate tumours even 
after the development of androgen-insensitive disease (Craft et ah, 1999) (Grossmarm et 
ah, 2001) (Edwards et ah, 2003a) (Hobisch et ah, 1995). AR expression and activity is 
known to increase after long-term hormone-therapy and its’ expression continues with the 
development of metastatic AIPC (Culig et ah, 2002).
There is therefore strong evidence to support a crucial role for the AR-signalling pathway 
with the development of AIPC. As a consequence of this, the majority of research into the 
mechanisms of androgen-escape has focused on how alterations and aberrant stimulation 
of the AR at a molecular level can re-activate AR signalling, with or without ligand- 
binding. Two hypotheses have emerged as a result - the first implicating genetic 
modifications (mutations and amplification) of the AR, and, more recently, a second 
focusing on post-translational modification of the AR, specifically the role of cell 
signalling pathways in altering the activation status of the AR protein itself.
Several studies have focused on mutations of the AR binding domain in AIPC and 
amplifications of the AR gene leading to increased protein expression. These changes 
may lead to the abnormal functioning of the AR signalling pathway, despite continued 
androgen-blockade. This may subsequently allow increased sensitivity of the AR to low 
levels of circulating androgen produced by the adrenals or the AR may indeed respond to 
antiandrogens as well as other steroids (Culig et al., 2002) (Edwards and Bartlett, 2005) 
(Chen et ah, 2004;Culig et al., 1999).
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Several AR mutations have been characterised (Grossmann et ah, 2001) (Gottlieb et al.,
1998). Point mutations, in particular those involving the hormone-binding domain, can 
alter ligand binding affinity as well as transcriptional activity in cell-line studies - both 
resulting in cellular proliferation (Linja et al., 2001) (Wallen et al., 1999) (Culig et al.,
1998) (Grossmann et al., 2001) (Culig et al., 2002) (Edwards and Bartlett, 2005). 
Mutations in the N-terminal are more common in AIPC tumours (Wallen et al., 1999) and 
may allow binding of co-activators, with subsequent receptor activation in the absence of 
ligand binding (Edwards and Bartlett, 2005). Point mutations are not common in the early 
stages of prostate cancer, but are known to be more prevalent in cases of metastatic 
disease and AIPC (Lee and Chang, 2003) (Marcelli et ah, 2000) (Culig et al., 2002) 
(Suzuki et al., 1996). Alterations to the AR can also have paradoxical short-term effects. 
Certain point mutations, in particular, are thought to lead to the “antiandrogen-withdrawal 
syndrome” (Kelly and Scher, 1993) (Suzuki et al., 1996) (Miyamoto et al., 2004).
Amplifications of the AR have been consistently linked with androgen-escape (Bubendorf 
et al., 1999) (Linja et al., 2001) (Edwards et al., 2004) (Visakorpi et al., 1995). Up to a 
third of androgen-independent tumours contain amplification of the AR gene, a 
phenomenon seen much less frequently in primary tumours (Bubendorf et al., 1999) 
(Edwards and Bartlett, 2005) (Linja et al., 2001) (Koivisto et al., 1997) (Edwards et al., 
2003a). Not surprisingly, increased levels of AR expression with the development of 
AIPC have also been reported (Linja et al., 2001) (Trapman and Cleutjens, 1997) (Suzuki 
et al., 2003) (Hobisch et al., 1995) and often in association with gene amplification 
(Koivisto and Rantaia, 1999) (Edwards et al., 2003a). Studies using paired androgen- 
sensitive and insensitive human prostate xenografts have confirmed that increased AR 
expression occurs consistently with the development of androgen-insensitive disease, and
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can also sensitise the AR to low levels of androgen and antiandrogen (Chen et al, 2004). 
AR protein expression has also been shown to coiTelate with tumour grade, stage and 
disease-free survival, as well as predicting patient response to therapy (Trapman and 
Cleutjens, 1997) (Koivisto and Rantaia, 1999) (Edwards et al., 2003a). One study 
revealed improved response to MAB in patients with AR amplification compared to those 
without (Pahnberg et ah, 1997).
AR mutations and gene amplification are not however seen in all AIPC tumours (Edwards 
et al., 2003a) (Culig et al., 2002). Whilst mutations are more commonly found in in vitro 
models of AIPC, they appear to be a relatively infrequent occurrence in clinical metastatic 
disease and AIPC (albeit more frequent when compared with clinical ASPC) (Linja et al., 
2001) (Suzuki et al., 2003). Their presence may simply be secondary to an unstable 
genome resulting from advanced disease rather than a reflection of mutations promoting 
disease (Edwards and Bartlett, 2005). In addition, these receptors generally camiot bind 
androgen or have decreased transcriptional activity (Culig et al., 2002). Furthermore, 
mutations are also too infrequent to account for the majority of patients who develop the 
antiandrogen-withdrawal syndrome. Patients who do not possess AR mutations eventually 
develop andro gen-independent disease suggesting mechanisms other than AR mutations 
result in tumour progression (Lee et a l, 2002). As a result there is little clinical evidence 
cuiTently linking specific mutations with the development of AIPC, although the 
possibility of mutations resulting in at least a small sub-group of patients developing 
androgen-insensitive disease cannot be ruled out (Edwards and Bartlett, 2005).
Amplification of the AR gene does not always have functional consequences in terms of 
protein expression. Furthermore, mutations as well as amplifications in ASPC tumours do
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not predict poor response to treatment (Edwards and Bartlett, 2005). AR amplification has 
not been shown to correlate with time to relapse or disease progression once AIPC is 
established (Culig et ah, 2002) (Edwards et ah, 2003a). Not every patient responds or 
behaves in a similar fashion to androgen-deprivation therapy and it is now clear therefore 
that tumours may utilize more than one survival mechanism in order to develop androgen- 
independence. Our laboratory has demonstrated amplification of AR prior to androgen 
therapy in a patient who had a full clinical response to androgen-deprivation, and whose 
AR expression fell once AIPC developed (despite on-going amplification) (Edwards et 
al., 2003a). This suggests that AR amplification does not necessarily negate a positive 
response from therapy and therefore may not be essential for the development of 
androgen-escape (Edwards and Bartlett, 2005). In another study using matched pairs of 
ASPC and AIPC patient specimens, AR amplification, whilst seen more frequently, was 
still present in only 20% of cases of AIPC (Edwards et ah, 2003a), Although 80% of 
tumours with AR amplification also had raised AR expression, AR expression was also 
seen in 35% of cases with no amplification.
This supports the role of alternative mechanisms resulting in increased AR expression in 
the absence of amplification, such as up-regulation of mRNA, protein stabilisation or 
decreased protein degradation (Gregory et ah, 2001b) (Linja et ah, 2001) (Edwards and 
Bartlett, 2005). AR expression in animal models has been shown to induce AIPC, 
independently of increased gene copy number (Chen et ah, 2004). Conversely, AR 
downregulation has also been demonstrated in cell-lines showing metastatic properties 
(Culig et ah, 2002) and in some AIPC patients (Linja et ah, 2001). Hypermethylation of 
the AR gene promoter region, which is seen more frequently in AIPC, has been forwarded 
as a mechanism of inliibiting AR gene transcription and protein expression despite
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amplification and may occur in up to 15% of tumours (Linja et aL, 2001) (Suzuki et al.,
2003) (Culig et al., 2002). Correlation between AR gene amplification and expression of 
the androgen-dependent gene, PSA (which one might expect in AIPC even with androgen 
deprivation) has been noted in some studies but not others, reflecting the complex nature 
of androgen-dependent gene expression (Linja et ai., 2001).
Therefore evidence in the literature, including our own data, questions the role of 
androgen-receptor modification at the genetic level in the development of androgen- 
escape. Whilst they may remain clinically relevant, the occurrence of both amplifications 
and mutations are too infrequent to account for the majority of cases of AIPC (Chen et ah,
2004). There must be alternative mechanisms or pathways regulating AR activation. It is 
not surprising that, unlike breast cancer where oestrogen and progesterone receptor status 
have prognostic and diagnostic relevance, AR status has not achieved this in prostate 
cancer (Culig et al., 2002).
I.2.I.3. Post-Translational Modifications of the AR in AIPC
Recent findings have therefore increased our understanding of the role of the AR in AIPC. 
As a result, studies have now shifted to the analysis of AR post-translational 
modifications. In particular, expression and function of signal transduction pathways 
and/or co-activators can activate the AR independent of androgens.
The entire sequential cascade of steps initiated upon ligand-binding to the AR is inherently 
dependent on diverse but key phosphorylation events. Protein phosphorylation plays a key 
role in regulating steroid hormone activity, such as DNA binding and activation of 
transcription (Zhu and Liu, 1997) (Rochette-Egly, 2003). Phosphorylation of the AR was
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first described in 1990 (Edwards and Bartlett, 2005). Binding of androgen initiates 
hyperphosphorylation by various protein kinases at multiple and specific serine residues in 
the N-terminal AF-1 (and LBD AF-2) region (Rochette-Egly, 2003). This protects the AR 
from proteolytic degradation, leading to increased stability of the ligand-receptor complex 
and, importantly, increases transcriptional activity (Wen et al., 2000) (Zhou et al., 1995) 
(Blok et al., 1998) (Lee and Chang, 2003) (Rochette-Egly, 2003). Protein kinase activity 
on the AR, and its’ co-activators, therefore acts synergistically with hormone/ligand to 
achieve maximal AR transcriptional activity (Rochette-Egly, 2003).
However AR phosphorylation and activity is not just dependent on receptor or ligand 
concentration nor even ligand binding, as other mechanisms may allow androgen- 
independent phosphorylation of the AR (Edwards and Bartlett, 2005) (see Figure 4). 
Phosphorylation at different, but specific, consensus serine and proline peptide sequences 
can be mediated by a variety of cytokines and growth factors which act as ligands for 
tyrosine-kinase receptors (Rochette-Egly, 2003). These in turn stimulate several intra­
cellular protein kinase signal transduction cascades, which enter the nucleus to act on the 
AR (Rochette-Egly, 2003). Cross-talk with these signalling pathways may promote the 
activation of the AR even in the absence of androgens (Rochette-Egly, 2003) (Craft et al.,
1999) (Edwards and Bartlett, 2005). For example, in vitro studies have already 
demonstrated that activation of the MAP Kinase and Akt signal transduction cascades can 
result in phosphorylation of the AR (Chen et ah, 2004) (Abreu-Martin et al., 1999) (Yeh et 
al., 1999) (Wen et al., 2000) (Bakin et al., 2003) (Rochette-Egly, 2003). This results in 
AR-mediated transcription with or without androgen. MAP Kinase can phosphorylate the 
NTD AF-1 region of the AR at serine 515 while Akt phosphorylates at serine 210, both 
aiding recruitment of co-activators. In addition, the LBD also contains sites that act as
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targets for ligand-independent phosphorylation by intra-cellular kinases (Rochette-Egly,
2003). The resulting increase in the transcription o f target genes and their growth 
stimulatory effects may therefore be a mechanism o f AIPC development.
Figure 4. Interaction o f Signal Transduction Pathways with the Androgen Receptor
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Phosphorylation and activation o f  the AR can therefore occur via cross-talk with growth 
factor and cytokine-mediated signalling pathways. In vivo, this may allow the AR to be 
activated in the absence o f androgens, to other steroids, or at the very least sensitised to the 
low levels o f circulating adrenal androgens that are present during androgen-deprivation 
therapy (Chen et al., 2004) (Rochette-Egly, 2003). The AR gene itself contains AREs 
implying a self-regulating, but potentially positive feedback mechanism upon over­
activation o f the AR-pathway, which would result in its’ own upregulation (Chen et al.,
2004).
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AR activation may therefore be affected in many ways, at multiple levels, and with 
differing results. However, there is no evidence as yet that phosphorylation of the AR by 
other pathways can induce homodimer formation, or that ligand-independent activation 
always leads to cell proliferation. Furthermore, the on going and rising expression of PSA 
in AIPC may suggest that, despite AR suppression, AR-independent mechanisms can 
occur and are responsible for tumour growth. The AR-signalling pathway might in fact be 
bypassed completely by activation of regulatory molecules capable of effecting the 
transcription of androgen-dependent genes e.g. AP-1, p53, bcl-2, and neuroendocrine 
factors (Grossmann et al., 2001).
The alteration in the expression and function of signalling cascades involved in AR 
regulation could therefore result in tumour proliferation with or without involvement of 
the AR-signalling pathway. Targeting of these signalling pathways may seiwe as a future 
therapeutic strategy, for example through the use of monoclonal antibodies directed at 
growth factor receptors, inhibition of receptor tyrosine kinase activity or via the specific 
inliibition of cell signalling molecules (such as MAP Kinase or Akt) (Agus et al., 1999) 
(Morris et al., 2002) (Wen et ai., 2000) (Lee et al., 2002). However much of the data 
involving their role in the molecular basis of AIPC has resulted from in vitro studies, and 
their presence in clinical AIPC remains undefined (Chen et ah, 2004). It is therefore vital 
to determine the clinical importance of these signal transduction cascades with reference 
to AIPC patients using clinical material (Grossmami et al., 2001). To this effect, our 
laboratory has already identified 2 members of the MAP kinase pathway (hRas and Raf-1) 
whose genes are amplified more commonly in androgen-insensitive compared to 
androgen-sensitive prostate cancer (Edwards et ah, 2003b).
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1.3 Signal Transduction Pathways associated with AIPC
1.3.1 IL-6 and the JAK/STAT Pathway
Among the various pathways known to regulate AR activity, the IL-6 cascade is thought 
to play an important role. IL-6 was originally described as a regulator of the immune and 
inflammatory responses, but is now known to influence tumour cell growth in an 
autocrine/paracrine manner (Ueda et al., 2002b). The IL-6 receptor (IL-6R) contains the 
signal transducer gpl30 which, upon ligand-binding, dimerises and activates the Janus 
kinases (JAK). The signal transducer and activator of transcription 3 (STATS) protein is 
the main target of IL-6R(Culig et al., 2002) (Ueda et al., 2002b) (Grossmann et al., 2001) 
and, upon tyrosine phosphorylation by JAK, migrates to the nucleus and initiates 
transcription (Ueda et al., 2002b) (Figure 5). It has already been suggested that activation 
of the JAK/STAT3 pathway via IL-6R plays an important role in ligand-independent 
activation of the AR, and may be a factor in the development of AIPC (Ueda et al., 
2002b) (Chen et ah, 2002). Activated STATS has been shown to bind the AR, 
independently of ligand, and subsequently transcribe androgen-regulated genes in LNCaP 
cells (Ueda et ah, 2002b) (Chen et ah, 2002). Expression of PIAS (protein inhibitor of 
STATS) is known to reduce AR activity (Chen et ah, 2002). Whilst the PSA gene does 
not contain STATS binding sites, so camiot be transcribed by it directly, STATS has been 
shown to directly interact with amino acids 234-558 of the AR (Ueda et ah, 2002b). 
Furthermore, the AR can be activated by IL-6R by phosphorylation at the NTD, resulting 
in increased PSA expression and cellular proliferation, independently of androgen, in 
LNCaP and DU-145 cell lines (Ueda et ah, 2002b) (Hobisch et ah, 1998). This may be 
mediated via STATS or MAP Kinase. Subsequent addition of low amounts of androgen 
synergistically increases PSA expression (although not proliferation), further implicating 
IL-6 in clinical AIPC development. IL-6R can activate MAP Kinase directly through JAK
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(Ueda et al., 2002b), or indirectly via a gpl30-mediated interaction and activation o f  
HER2 (Qiu et al., 1998). Furthermore, MAP Kinase may in turn activate STATS (Ueda et 
al., 2002b), indicating a critical role for MAP Kinase in merging or focusing signal 
cascades into a common pathway (Figure 5). Finally, in AR negative cells, IL-6R has 
also been shown to interact with the PISK/Akt pathway (Chung et al., 2000).
Figure 5. The IL-6/JA K /ST A T Pathway and its’ interaction with the A R  and  
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In vitro models o f  AIPC have also demonstrated upregulation o f IL-6R mRNA and 
protein expression (Hobisch et al., 2000) (Culig et al., 2002). Both stimulatory and 
inhibitory effects on LNCaP cell growth have been reported (Hobisch et al., 1998) (Culig 
et al., 2002) (Ueda et al., 2002b), which may attributable to the number o f cell passages 
(Culig et al., 2002). The clinical relevance o f  IL-6R, however, remains unclear. IL-6 and 
IL-6 receptor are expressed in benign and malignant prostatic tissue. Serum IL-6 is 
elevated in AIPC, while protein expression o f IL-6R is upregulated in prostate cancer
tissue specimens (Culig et al., 2002) (Drachenberg et al., 1999) (Grossmann et al., 2001) 
(Edwards and Bartlett, 2005) (Ueda et al., 2002b) implying that autocrine or paracrine 
loops are being formed (Hobisch et al., 2000). This may involve the transcription factor 
NFkB, which positively regulates the secretion of IL-6 and promoter activity of the ÏL-6 
gene.
1.3.2 Type 1 Receptor Tyrosine Kinases -  The EGF-Receptor Family of Growth 
Factor Receptors
The epidermal growth factor receptor family of type 1 receptor tyrosine kinases has 4 
members -  EGFR (erbBl or HER 1), HER2 (erbB2 or neu), HER3 (erbB3), and HER4 
(erbB4). In addition, there exist mutated forms such as the constitutively-active form of 
the EGFR - variant III EGFR (EGFR vIII). Increased expression of EGFR, HER-2 and 
EGFR vIII has all been described in prostate cancer (Craft et al., 1999) (Olapade-Olaopa 
et al., 2000).
Upon binding of ligand, EGFR dimerises and activates downstream signal transduction 
pathways. EGF has been shown to activate AR in the absence of androgen in DU-145 
cells (Culig et ah, 1994) although contradictory findings have also been reported, which 
may reflect differences in cell-line differentiation (Ueda et ah, 2002b). Both ligand- 
dependent and independent effects on AR activity have been reported, however EGF is a 
less potent stimulator of the AR than androgen (Gupta, 1999). EGFR may be upregulated 
by androgenic hormones (Culig et al., 2002). Interestingly, progressive loss of EGFR has 
been noted with the progression of prostate cancer (Olapade-Olaopa et al., 2000). This 
may be a result of EGFR vIII overexpression, resulting in dysregulated growth 
independent of ligand (Edwards and Bartlett, 2005). Consistent with this, it has been
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shown that EGF vIII expression is markedly increased in prostate cancer specimens 
(Olapade-Olaopa et ah, 2000).
HER2 contains intrinsic tyrosine kinase activity, and is thus able to activate downstream 
pathways in the absence of ligand (Wen et ah, 2000). HER2 amplification has been shown 
in several cancers Including AIPC, and is associated with a poor prognosis. Only low- 
level heterogeneous HER2 amplification, however, is observed in prostate cancer 
(Ouyang et ah, 2001) (Kaltz-Wittmer et ah, 2000) (Bartlett et ah, 2005). Amplification of 
the HER2 gene has been implicated with other endocrine neoplasms including breast and 
ovarian cancers (Slamon et ah, 1989). HER2 status predicts failure of anti-oestrogen 
therapy, and is associated with decreased survival in node positive breast cancer (Leitzel 
et ah, 1995). Overexpression has also been linked to neovascularisation in breast cancer 
(Ross et ah, 1997) and has been shown to induce cyclo-oxygenase-2 (COX-2) expression 
in colorectal cancer (Vadlamudi et ah, 1999). The use of herceptin, a monoclonal 
antibody directed at preventing HER2 activation, is now well established clinically in 
advanced breast cancer in combination with chemotherapy (Craft et ah, 1999) (Solit and 
Agus, 2001).
As a result of its’ successful translational-based research in breast cancer, HER2 activity 
has been studied extensively with relation to the development of AIPC (Yeh et ah, 1999) 
(Craft et ah, 1999) (Solit and Agus, 2001). Overexpression and/or gene amplification of 
HER2 has been noted in clinical AIPC as well as in the pre-malignant pro static 
intraepithélial neoplasia (PIN), suggesting a role in prostatic carcinogenesis (Grossmann 
et ah, 2001) (Morris et ah, 2002) (Signoretti et ah, 2000) (Ross et ah, 1997) (Kuhn et ah, 
1993) (Mellon et ah, 1992). Gene amplification and increase copy number has also been
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shown to correlate with high Gleason score, poorer prognosis and androgen resistance in 
several studies but not others (Craft et ah, 1999) (Sadasivan et ah, 1993) (Shi et ah, 2001) 
(Wen et ah, 2000) (Ross et ah, 1997) (Solit and Agus, 2001). Consistent with other 
reports, work in this laboratory using matched ASPC and AIPC tumours demonstrated 
that, although amplification of HER2 is not associated with hormone relapse, increased 
protein expression significantly impacts on patient survival (Bartlett et ah, 2005). In 
support of this, it has been demonstrated that HER2 expression increases in the 
progression from androgen-sensitive to androgen-insensitive disease in both cell-line 
studies and xenograft studies, reversing growth an'est and allowing ligand-independent 
growth via the AR (with a concomitant increase in PSA expression) (Craft et ah, 1999) 
(Agus et ah, 1999) (Yeh et ah, 1999). In addition, synergistic growth in the presence of 
low levels of androgen has also been noted. Serum levels of HER2 extracellular domain 
have also been correlated with AIPC (Arai et ah, 1997), and may be related to variable 
tumour protease activity (Solit and Agus, 2001).
Interestingly, unlike EGFR, HER2 activation of the AR cannot be blocked by the 
antiandrogen bicalutamide, which acts at the ligand-receptor interface. This indicates a 
different and more distal site of interaction between FIER2 and the AR compared with 
EGFR, and provides a mechanism for AIPC development (Craft et ah, 1999) (Yeh et ah,
1999). HER2 cross-talk with the AR may involve a signal transduction pathway resulting 
in post-translational modification of the AR as discussed earlier (perhaps in combination 
with activation of a co-activator or accessory protein involved in the transcription 
complex) (Craft et ah, 1999) (Yeh et ah, 1999). HER2 is known to activate the MAP 
Kinase pathway (Ben Levy et ah, 1994) and its’ overexpression can stimulate 
proliferation of LNCaP cells via MAP Kinase (Craft et ah, 1999). Concurrent PSA
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expression falls upon addition of the MAP Kinase inhibitors (Yeh et a l, 1999). 
Interestingly, simultaneous addition of ARA-55 and ARA-70 increases AR transactivation 
synergistically with HER2 (Yeh et al., 1999). This study therefore suggests a role for 
HER2 in promoting ARA-AR interaction, via MAP Kinase. HER2 may also be a central 
component of IL-6 signalling via MAP Kinase in prostate cancer, as has been 
demonstrated in LNCaP and DU-145 cell lines (Qiu et al., 1998). Although MAP Kinase 
inhibition decreases, it does not completely block PSA expression via HER2-AR 
activation, implying that HER2 can act via other signal cascades. In support of this, HER2 
(and EGFR) are both known to activate the PI3K/Akt pathway, promoting tumourigenesis 
via the AR in the absence of androgen (Zhou et ah, 2000) (Wen et ah, 2000).
As a result of their possible role in advanced prostate cancer, type 1 receptor tyrosine 
kinases may provide a novel target for antibody therapy such as Herceptin and Iressa 
1701). A recent phase II study using a bispecific antibody against HER2, involving 25 
patients with HER-2 positive hormone refractory prostate cancer, has yielded promising 
results (James et ah, 2001). A phase Ib/II trial of the anti-EGFR monoclonal antibody 
cetuximab, in combination with the doxorubicin, produced stable disease in 38% of 
androgen independent prostate cancer patients (Slovin et ah, 1996). Studies investigating 
androgen independent prostate cancer xenograft models have reported positive results 
with herceptin especially in combination with paclitaxel (Agus et ah, 1999).
The current data therefore supports the hypothesis that signal transduction cascades, and 
such as the Raf/MAP Kinase pathway, can act as mediators for the modulation and 
ligand-independent activation of the AR by HER2 in patients with AIPC. However there 
is no data as yet to support this using clinical material.
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1.3.2.3 PI3K/Akt Pathway
The PIBK/Akt pathway plays a key role in the control of cell proliferation and survival. 
Overexpression of the pathway has therefore been implicated in prostatic carcinogenesis. 
Constitutive activation of PI3K (phosphatidylinositol 3-kinase) or Akt can induce cellular 
transformation (Davies et al., 1999). PI3K phosphorylates phosphatidylinositol to 
phosphatidylinositol triphosphate (PIP3), which binds and contributes to the activation of 
the serine-threonine kinase Akt (or protein kinase-B). Akt subsequently migrates to the 
cell membrane at which point phosphorylation, by the phosphoinositide-dependent protein 
kinases 1 and 2 (PDKl and PDK2), results in its’ complete activation. Akt goes on to 
inhibit pro-apoptotic proteins (such as BAD) and activate proteins involved in cell 
proliferation (such as inTOR) (Grossmann et al., 2001) (Gao et al., 2003) (see Figure 6).
Inactivation of PTEN (phosphatase and tensin homologue deleted on chromosome 10), an 
inliibitor of PI3K, by mutations and deletions is known to occur in advanced prostate 
cancer (Culig et al., 2002) (Fenci and Woenckhaus, 2002) (Li et al., 2001). The 
subsequent activation of PI3K7Akt phosphorylates BAD, leading to increased bcl-2 
activation (a known inhibitor of apoptosis) (see Figure 6) (Grossmami et al., 2001). 
Overexpression of bcl-2 has also been implicated in AIPC development, perhaps seiwing 
as another mechanism to bypass the AR pathway (Grossmann et al., 2001) (Chen et al.,
2004). However, PTEN is also known to cause regression and inliibition of AR activity 
via inhibition of PI3K, thereby inducing apoptosis and suppression of PSA (Li et ah,
2001). Overexpression of bcl-2 in LNCaP cells blocks PTEN-induced apoptosis but not 
growth suppression, implying other regulatory effects of PTEN and PI3K/Akt (Davies et 
al., 1999). Interestingly, AR activity may be reduced by phosphorylation at serine 210 in 
the NTD - the site of action of Akt - disrupting co-activator binding (Edwards and
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(Bartlett, 2005). This may lead to diminished expression o f the pro-apoptotic androgen- 
regulated gene, p21/W AFl. The PI3K/Akt pathway has therefore been shown to promote 
prostate cancer cell survival and growth both via and independently o f the AR (Lin et ah,
2001) (Sharma et ah, 2002).
Figure 6. The P13K/Akt Pathway
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Whilst withdrawal o f androgen triggers apoptosis in androgen-sensitive tumours, this does 
not oecur in AIPC (Grossmann et ah, 2001). Upregulation o f Akt appears to compensate 
for this in LNCaP cells (Gao et ah, 2003) and Akt activity is also known to be greater in 
AIPC tumour cell lines (Graff et ah, 2000) (Nakatani et ah, 1999). Its’ expression 
increases in high-grade tumours, correlating with serum PSA (Fenci and Woenckhaus,
2002) (Liao et ah, 2003). Akt ean increase AR expression in LNCaP eells (Manin et ah,
2002) and activate PSA expression in the absence o f androgen (Wen et ah, 2000). It has
# been suggested, therefore, that androgen-deprivation may promote AIPC by stimulating a 
HER2/PI3K/Akt pathway, resulting in cell survival and indeed cellular proliferation (Wen 
et ah, 2000) (Lin et al., 2001).
This data would imply that the PI3K/Akt pathway may have a significant role to play in 
the development of AIPC, either thiough the prevention of apoptosis or by stimulation of 
androgen-regulated genes possibly via the AR. PI3K is known to be activated by IL-6 as 
well as EGFR and HER2 (Grossmann et ah, 2001) (Wen et al., 2000) and Akt can also 
crosstalk with the MAP Kinase pathway, a point which will be discussed later. In support 
of this, our laboratory has also demonstrated gene amplification of PI3K and Akt as well 
as members of the MAP Kinase pathway with the development of AIPC (Edwards et ah, 
2003b). Further studies are therefore required to determine the full clinical role of the 
PI3K/Akt pathway in the development of AIPC.
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1.4 The Raf/MAP Kinase Pathway Signal Transduction Cascade
1.4.1 Background Role in Carcinogenesis
The Raf/MAP Kinase pathway is a signal transduction cascade that plays an important 
role in cellular proliferation, differentiation and apoptosis (Zhu and Liu, 1997). Several 
growth factors are known to stimulate the pathway via receptor tyrosine kinases. Once 
activated the membrane-bound GTPase, Ras, phosphorylates the Raf family of 
serine/tlireonine kinases, of which Raf-1 is ubiquitously expressed (Weinstein- 
Oppenheimer et ah, 2000). When activated, by phosphorylation at the serine 338 
position, Raf translocates to the membrane where it activates the MAP Kinase kinases 
(or MEKs). This results in a cascade of successive phosphorylation steps, culminating in 
activation of p42/44 MAP Kinase at specific tyrosine and threonine sites (Weinstein- 
Oppenheimer et ah, 2000) (see Figure 7). Several other protein kinase pathways, once 
activated, are also known to converge on the MAP Kinase cascade (Rochette-Egly,
2003). In turn, MAP Kinase has a variety of downstream targets including other protein 
kinases, receptors for hormones and growth factors, and nuclear transcription factors. 
Given its’ role in cellular development, disruption to the pathway is thought to result in 
pathological changes such as carcinogenesis.
Alterations to any member of the Raf/MAP kinase pathway have therefore been linked 
with the progression of several cancers (Weinstein-Oppenlreimer et ah, 2000) (Khleif et 
ah, 1999) (Ito et ah, 1998) (Oka et ah, 1995). MAP Kinase is known to activate the 
oestrogen receptor in breast cancer eells upon stimulation by oestradiol or EGF (Kato et 
ah, 1995) (Bunone et ah, 1996). Prostate cancer cell-line studies have also revealed 
increased cell proliferation via type 1 receptor tyrosine kinase activation of the MAP 
Kinase pathway (Bell et ah, 2003). Up-regulation may lead to androgen-independent
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activation of the AR via phosphorylation of the AF-1 domain as mentioned previously 
(Feldman BJ and Feldman D, 2001) (Rochette-Egly, 2003). Furthermore, in vitro studies 
have demonstrated that activation of the Raf/MAP Kinase pathway may increase prostate 
cancer cell growth both via and independently of the AR, further implicating it in the 
development of AIPC (Abreu-Martin et al., 1999) (Bakin et al., 2003) (Yeh et al., 1999) 
(Zhu and Liu, 1997).
Figure 7. The Raf/M A P K inase Pathway
MAI*
Kinusr
activation (Edwards and Bartlett, 2005). Mutated Ras has been linked with increased 
levels of activated MAP Kinase and the development of androgen-independent growth in
LNCaP cells (Bakin et al., 2003) (Voeller et al., 1991). Activated MAP Kinase and MEK 
are also differentially expressed during the progression of prostate cancer in a transgenic 
mouse model (Uzgare et ah, 2003). Raf and MEK are expressed in both non-metastatic 
and metastatic prostate cancer cells (Weinstein-Oppenheimer et ah, 2000) (Fu et al.,
2003). Increased MAP Kinase activity is known to be elevated in androgen-insensitive 
eell-lines and in clinical AIPC (Abreu-Martin et al., 1999) (Gioeli et al., 1999). 
Intriguingly, the constitutively active form of MAP Kinase also induces Raf-1 activation 
in cell-line studies, forming the positive feedback loop required for chronic autocrine 
stimulation (Weinstein-Oppenheimer et al., 2000).
MAP Kinase can also increase transcription of androgen-dependent genes, independently 
of androgen, via phosphorylation of the AR or AR eofactors (Abreu-Martin et al., 1999) 
(Bakin et al., 2003) (Ueda et al., 2002b) (Rochette-Egly, 2003) (Franco et al., 2003). 
MAP Kinase is known to activate the AR NTD by phosphorylation of serine 515 
independent of androgen (Yeh et ah, 1999) (Rochette-Egly, 2003). Inhibition of MAP 
Kinase in cell-line studies is known to abrogate IL-6 and protein kinase-A (PKA) 
activation of the AR, suggesting a crucial role in the convergence of both pathways 
towards the AR NTD (Ueda et ah, 2002b). Hydroxyflutamide has been shown to activate 
the Raf/MAP Kinase pathway independently, stimulating cell proliferation, possibly via 
a member of the EGFR receptor family (Lee et ah, 2002). Activation of the pathway has 
therefore been linked with the pathogenesis of the androgen-withdrawal syndrome, by 
stimulating androgen-independent cell growth in response to antiandrogens. Data has 
also revealed increased activation of the MAP Kinase pathway with the clinical 
progression of prostate cancer (Lee et ah, 2002) (Gioeli et ah, 1999) (Magi-Galluzzi et 
ah, 1997) (Magi-Galluzzi et ah, 1998). Taken together, the MAP Kinase pathway
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» appears to play a crucial role in cross-talking with the AR-signalling pathway and 
modulating its’ response to ligands. It may also function as a surrogate for ligand- 
activation during androgen withdrawal, resulting in the progression to AIPC.
The biological response of eells to activation of the Raf/MAPK pathway is dependent on 
their environment, which may explain its’ role in proliferation and differentiation as well 
as growth arrest (Zimmermann and Moelling, 1999) (Kolch, 2000). This varies from the 
type, duration and strength of external stimuli (e.g. growth factors/cytokines, androgen, 
temperature, osmolarity, and genotoxic stress in the form of irradiation or chemotherapy) 
as well as the particular cell type studied (Zhu and Liu, 1997) (Abreu-Martin et ah, 1999)
(Zimmermann and Moelling, 1999). For example, in the absence of androgen, MAP ' j
■IKinase kinase kinase (MEKK) activates transcription of androgen-regulated genes to
;
induce apoptosis, not cell growth, via the AR-signalling pathway in LNCaP cells (Zhu 4
and Liu, 1997) (Abreu-Martin et al., 1999). Addition of androgen increases this 
transcription synergistically. Therefore MAP Kinase activation can effect apoptosis upon 
androgen withdrawal. This may be mediated by AR-induced caspase activation or via 
direct stimulation of JNK (c-jun N-terminal kinase) (Zhu and Liu, 1997) (Abreu-Martin 
et ah, 1999) (Magi-Galluzzi et ah, 1997). Interestingly, antiandrogen treatment does not 
completely abrogate apoptosis or transcription of the PSA gene, which may be the result 
of a more distal site of MEKK activation on the AR pathway or may imply bypassing of 
the AR entirely. MEKK is also capable of inducing PSA expression 2-fold in the absence 
of the AR, which further supports this hypothesis.
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1.4.2 Downstream Effectors of the Raf/MAP Kinase Pathway
As discussed earlier, the MAP Kinase cascade can be activated by a variety of growth 
factor and cytokine receptors, of which the type 1 receptor tyrosine kinases are the most 
commonly studied in prostate cancer. Similarly, activation of MAP Kinase can have a 
variety of consequences. MAP Kinase is capable of direct phosphorylation of the AR in 
vitro, resulting in its’ activation. MAP Kinase may in fact effect AR post-translational 
modifications indirectly via other signal transduction cascades (Zhu and Liu, 1997) 
(Abreu-Martin et al., 1999). Members of the MAP Kinase cascade are capable of 
interacting with several other signalling molecules, such as the AR co-activators (e.g. 
ARAs and GRIP), in order to form large multi-protein complexes involving the AR itself 
and possibly aiding its’ activation (Abreu-Martin et al., 1999) (Bevan and Parker, 1999) 
(Fujimoto et al., 2001). The AR co-activator SRC-1 (steroid receptor co-activator) 
contains 2 potential phosphorylation sites for MAP Kinase (Suzuki et al., 2003) (Rowan 
et al., 2000). Activation of SRC-1 may therefore be an important route for androgen- 
independent AR activation tlnough its’ interaction with the AR NTD and LBD (Ueda et 
al., 2002a). As mentioned earlier, SRC-1 expression increases after hormone therapy and 
tumour recurrence (Gregory et al., 2001a) and it has been shown to enhance androgen- 
independent activation of the AR in LNCaP cells (Edwards and Bartlett, 2005). Whether 
these events occur in prostate cancer cells in vivo is not yet known, but MAP Kinase may 
well act on the AR directly via phosphorylation and indirectly via activation of co­
activators.
Simultaneous phosphorylation of steroid receptors as well as other transcription factors, 
resulting in differing transcription events, has been described (Rochette-Egly, 2003). 
MAP Kinase can ftinction tlnough transcription factors such as AP-1 (activated protein-1 
- a heterodimer formed between c-fos and phosphorylated c-jun), Elk-1, c-myc as well as
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NF-kB. These may co-operate with the AR resulting in activation of androgen-dependent 
genes (Bubulya et ah, 2001) (Sato et ah, 1997) (Wise et ah, 1998). MEKK can target c- 
jun N-terminal kinase (JNK) which is required for AP-1 activity in vitro. In addition, c- 
jun can interact with the NTD and hinge region of the AR, promoting homodimerisation 
and increasing its’ transactivation ability, even in the absence of ligand (Wise et ah,
1998) (Bubulya et ah, 2001). C-jun can also prevent the inlhbitory effects of the AR co­
repressor p53 (Lee and Chang, 2003), which may be another mechanism by which MAP 
kinase activates the AR to effect androgen-independent growth (Zhu and Liu, 1997).
The PSA promoter site itself contains binding sites for various transcription factors, 
including AP-1, possibly allowing for AR-independent transcription via the MAP Kinase 
pathway. The MAP Kinase pathway is known to stimulate AP-1 transcriptional activity 
in both AR-positive and negative cells (Abreu-Martin et ah, 1999). Activation of the 
natural PSA promoter in the absence of androgen may occur as a result of such ARE- 
independent effects, as use of an artificial template in cell-line work required ligand- 
binding activation of the AR (Abreu-Martin et ah, 1999). Activated MAP Kinase 
therefore may stimulate prostate cancer cell growth independently of the AR in vivo via 
activation of transcription factors such as AP-1 (Weinstein-Oppenheimer et ah, 2000). 
Work in our own laboratory has already linked increased AP-1 expression with 
androgen-resistance and decreased patient survival (Edwards et ah, 2004).
1.4.3 Raf-1
Raf-1 is ubiquitously expressed and is regarded as the main Raf molecule. As a result it 
has become the most studied and best characterised member of the MAP Kinase cascade 
(Dhillon et ah, 2003). Raf-1 connects with a variety of upstream extracellular signals
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(through cell surface receptors) integrating and relaying their signals downstream to effect 
nuclear transcription via other members of MAP Kinase cascade (Dhillon et ah, 2002a). It 
acts as the sole entry point to the MAP Kinase cascade, via its’ activation of MEK 
(Dhillon et ah, 2002b) (Tzivion et ah, 1998). The Raf/MAPK pathway is therefore 
regarded as a linear pathway due to the narrow range of substrates each member of the 
pathway has i.e. Raf-1 activates MEK only and MEK only activates MAP kinase (Dhillon 
et ah, 2003).
Inactive Raf-1 in the cytoplasm is bound to the HSP90, HSP50, Cdc37 and 14-3-3 
proteins (Tzivion et ah, 1998). Its’ activation depends predominantly (but not entirely) on 
receptor activation of GTP-bound-Ras which binds to the N terminal domain of Raf-1 - 
primarily to the Ras-binding domain (RBD) of Raf-1, but also to the Raf-1 cysteine-rich 
domain (CRD) via its’ farnesylated tail (Dhillon et ah, 2002a) (Abraham et ah, 2000). Raf 
is the main effector of Ras (Dhillon et ah, 2003), and Ras is activated itself at the site of 
receptor tyrosine kinases by binding to GTP. This is catalysed tlnough activation of 2 
proteins, Grb-2 (growth factor receptor bound protein-2) and SOS (guanine-nucleotide 
exchange factor “son of sevenless”). Upon binding to Ras, Raf translocates from the 
cytoplasm to the plasma membrane where a multistep activation process takes place. This 
involves phosphorylation of the serine 338 and tyrosine 341 residues (Dhillon et ah, 
2002a). Only a small fraction of Raf-1 is actually activated, however, and subsequently 
released from the membrane back into the cytoplasm (Dhillon et ah, 2002a) (Dhillon et 
ah, 2002b) (Tzivion et ah, 1998).
In resting cells, the phosphorylation status of 3 serine residues in the N-terminal 
(regulatory) domain of Raf-1 -  serines 43, 259, 621 - play a crucial role in the regulation
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of Raf-1 activation and its’ downstream signalling ability (Dhillon et al., 2002b). Serine 
259 is the main inhibitory phosphorylation site and as such plays a pivotal role in Raf-1 
activation (Dhillon et ah, 2002b), mediating binding of the 14-3-3 protein which results in 
Raf-1 inactivation (Tzivion et al., 1998). This in turn interferes with phosphorylation of 
the serine 338 activation site (an essential activating site of Raf-1 in the kinase domain), 
and possibly disrupts the interaction with Ras (Zimmermann and Moelling, 1999) 
(Dhillon et al., 2002a) (Dhillon et ah, 2002b). The physical presence of a phosphate group 
at serine 259 is necessary for this inhibition (Dhillon et ah, 2002b). Conversely, Ras- 
mediated dephosphorylation of serine 259 reduces binding to 14-3-3, selectively (i.e. does 
not interfere with the serine 621 site, which is the other binding point of 14-3-3). This 
promotes membrane translocation, from its’ inactive state in the cytoplasm, and making it 
accessible for further dephosphorylation and activation by the enzyme phosphatase, PP2A 
(Dhillon et ah, 2002a). Dephosphorylation on serine 43 and 621 in resting cells, which is 
also essential for Raf-1 function (Abraham et ah, 2000) (Tzivion et ah, 1998), is possibly 
mediated by phosphatase PP2A, which binds Raf-1 at the cell membrane. This in turn 
prevents formation of inactive 14-3-3 complexes (Abraham et ah, 2000). Ras binding also 
induces the subsequent phosphorylation of serine 338, at the cell membrane (Dhillon et 
ah, 2002a).
Raf activity is therefore dependent on phosphorylation of serine residues and the integrity 
of the 14-3-3 dimer. Binding of the 14-3-3 protein stabilises inactive as well as active 
conformations, as its’ displacement can lead to deactivation of Raf-1 kinase activity and 
complete loss of catalytic function (Tzivion et ah, 1998). The inhibitory effect of serine 
621 may also be reversed by binding of 14-3-3 (Tzivion et ah, 1998) (Dhillon et ah, 
2002b). Dephosphorylation of serine 259, in response to Ras-stimulation, is also essential 
for and corresponds to peak activation of Raf-1 by facilitating its’ membrane translocation
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and further enhancing its’ interaction with Ras (Dhillon et ah, 2002a). Dephosphorylation 
of serine 259 therefore enhanees the catalytic activity of Raf-1, increasing coupling to and 
activation of MEK. PP2A-mediated dephosphorylation prevents further formation of 
inactive 14-3-3 complexes, increasing Raf-1 activation (Abraham et ah, 2000). This may 
be aided further thiough increased turnover of the Raf-1/MEK complex thiough an 
allosterie effect and binding of modulating proteins (e.g. Raf-1 inhibitory protein or 
RKIP) (Dhillon et ah, 2002a). Once phosphorylated at the membrane site, MEK 
dissoeiates to the cytosol (Dhillon et ah, 2002a). Mutations to the serine 259 site (to 
alanine, aspartate or glutamine) results in a constitutively active Raf-1 resistant to 
phosphorylation. This increases kinase activity because of enhanced binding to Ras 
(Zimmermami and Moelling, 1999) (Dhillon et ah, 2002a) (Dhillon et ah, 2002b). 
Mutated serine 259 is unable to bind 14-3-3 and also facilitates phosphorylation of serine 
338 to a greater degree.
Interestingly, whilst effecting cell proliferation in cell-line studies, mutated serine 259 
fails to induce the malignant transformation and differentiation associated with enlianced 
activation of the MAP Kinase pathway (Dhillon et ah, 2003). Mutations to serine 259 
therefore play a crucial role in governing the biological outcome of Raf-1 activation by 
altering its’ ability to activate the normal MAP Kinase pathway, perhaps indicating the 
existence of an alternative Raf-1 effector pathway separate to MAP Kinase. In support of 
this, Raf-driven inhibition of apoptosis has been noted to be independent of MAP Kinase 
(Dhillon et ah, 2003). This may be aided by upregulation of RKIP, which is known to 
disrupt Raf-1/ MAP Kinase coupling and also regulate cell transformation at multiple 
levels (e.g. suppression of NFkB).
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Phosphorylation of serine 338 acts synergistically with phosphorylation of the remaining 
activation site, tyrosine 341 (Dhillon et ah, 2002a). Phosphorylation of these activating 
sites is essential to but not sufficient for full activation of Raf-1 (Dhillon et al., 2002b), 
possibly combining to adjust Raf-1 activation to its’ proper level (Dhillon et al., 2002a). 
Phosphorylation of serine 338 and dephosphorylation of serine 259 show close correlation 
with the eatalytic activity of Raf-1, possibly co-regulated by PKA (Dhillon et al., 2002a). 
Hyperphosphorylation of serine 259 as well as serine 43 and 621 may be mediated by 
PKA, whose expression correlates with the level of inhibition of Raf-1 activity (Dhillon et 
al., 2002b). PKA therefore acts as a negative regulator of Raf-1, preventing a binding site 
for 14-3-3 and interfering with its’ binding to Ras (Dhillon et al., 2002b) (Abraham et al., 
2000). This provides the sole mechanism by which PKA crosstalks with and inhibits gene 
expression via the MAP Kinase pathway (Dhillon et al., 2002b). Mutant serine 259, 
interestingly, is resistant to PKA phosphorylation (Dhillon et ah, 2002b).
Akt has also been shown to antagonise Raf-1 activity by direct phosphorylation of serine 
259 -  providing another example of cross-talk between the pathways (Zimmermann and 
Moelling, 1999). Interestingly, this work, carried out on a breast cancer cell-line, 
demonstrated a proliferative response to PI3K-Akt pathway with transient activation of 
the Raf/MAPK pathway. The prolonged activation of Ras however inhibited growth. 
(Zimmermann and Moelling, 1999). It is already accepted that autocrine growth factors 
can stimulate multiple pathways, such as the Raf/MAP Kinase and PI3K/Akt pathways. 
Raf-mediated transformation may be induced when regulatory cross-talk with other signal 
cascades is disrupted, leading to the defective inhibition of Raf activity.
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1.5 Hypothesis and Statement of Aims
Although the Raf/MAP Kinase pathway has been implicated in the development of AIPC 
through cell-line and xenograft models (Bakin et ah, 2003) (Abreu-Martin et ah, 1999), 
its’ precise role in the development of clinical AIPC is still poorly understood. Earlier 
studies using clinieal tissue have revealed increased activated MAP kinase expression in 
only 2 and 4 patients respectively (Lee et ah, 2002) (Gioeli et ah, 1999). If clnonic 
autocrine stimulation of the pathway by growth factors results in progression to androgen- 
independent disease, one would predict increased expression and activation of members 
of the pathway (Gioeli et ah, 1999). The further elucidation of its’ role would clearly have 
therapeutic implications as in vitro studies suggest inhibition of the pathway, perhaps in 
conjunction with hormone therapy or chemotherapy, may provide a novel method of 
treatment in AIPC (Bakin et ah, 2003) (Zelivianski et ah, 2003).
We hypothesised, therefore, that the Raf/MAP Kinase pathway promotes the development 
of clinical AIPC. The purpose of this M.D. was to further investigate the role of this 
signal cascade in AIPC by determining if the genetic changes we have previously 
identified had functional consequences in terms of protein expression. We therefore 
proposed to investigate the role of the Raf/MAP Kinase pathway in clinical, archival 
material consisting of paired, matched histological tissue specimens obtained before 
commencement of androgen deprivation therapy and after the development of androgen- 
escape. We investigated expression levels and activation status of Raf-1 and MAP Kinase, 
2 critical members of the MAP kinase cascade, in these matched ASPC and AIPC 
tumours, using immunohistochemistry (IHC). We then correlated this expression with 
time to biochemical relapse, time to death from relapse and overall survival. We also 
correlated expression with that of the type 1 tyrosine kinase receptors, EGFR and HER2
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(known to activate the pathway), and the downstream targets, AR and AP-1, in the same
cohort of patients.
Project Aims
• To develop a pre-existing database of matched tissue specimens from 49 to 65 patients.
• To develop a tissue miero-array system and analyse its’ use in the study of AIPC.
• To determine protein expression of the Raf-1, including its’ active and inactive,
phosphorylated forms, in AIPC specimens using immunohistochemistry.
• To determine protein expression of p42/44 MAP Kinase, including its’ active,
phosphorylated form (pMAP Kinase), in AIPC specimens using 
immunohistochemistry.
• To correlate protein expression with time to biochemical relapse, time to death from
relapse, and overall survival
• To correlate expression with known upstream regulators and downstream targets,
including EGFR, HER2, AR, and AP-1.
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MATERIALS AND METHODS
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2.1 PATIENT RECRUITMENT AND TISSUE RETRIEVAL 
- EXPANSION OF ANDROGEN-ESCAPED DATABASE
The database used for the study consisted of matched pairs of tissue obtained sequentially 
from patients before androgen deprivation therapy and following the development of 
androgen escape. Patients were retrospectively selected for inclusion in the study if they 
had a full biochemical response to androgen deprivation therapy (as defined by falling 
serum PSA levels of at least 50%), but subsequently developed biochemical relapse (as 
confirmed by a sustained rise in PSA despite maximal treatment). Recruitment criteria 
therefore required the availability of androgen-sensitive or “naïve” tissue (i.e. prior to 
initial successful treatment). These sections originated from either a transuretlnal 
resection of the prostate (TURP) or from diagnostic transrectal ultrasound (TRUS) 
biopsies. Following the development of biochemical relapse, androgen-insensitive tissue 
was obtained from palliative TURP, carried out to relieve clinical outflow symptoms. This 
database originally consisted of 49 pairs, however this was expanded to 65 patients.
Twenty-one patients were recruited from Ayr Hospital after an extensive review of 
pathological records. From this search, patients with evidence of 2 or more separate 
prostatic biopsies were identified. Thereafter an extensive case note review was performed 
to identify those patients who satisfied the recruitment criteria as described above. The two 
sequential, paraffin-embedded tumour specimens from each patient (one taken before and 
one after the development of AIPC), were then retrieved from the pathological archives.
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In order to develop this cohort we received ethical approval from the Multiple Research 
Ethical Committee (MREC), the relevant Local Research Ethical Committees (LREC), as 
well as support from the Scottish Urological Oncological Group (SUGG), to enable us to 
recruit patients from throughout Scotland. LREC approval was obtained from the 
following NHS trusts: Ayrshire and Arran, Glasgow Royal Infirmary, Lanarkshire, 
Lothian, and Stirling. Ethical approval also included permission for the construction of 
tissue micro-arrays (TMAs) (see section 2.4). Once paraffin blocks were sectioned, the 
remaining tissue was returned to the hospital archives.
Full clinical follow-up was available for every patient in the database, including 
treatment information, survival statistics and PSA profiles tliroughout therapy (an 
example of which can be found in Figure 1 - see Appendix 1 for full clinical, 
pathological, and biochemical data of entire patient cohort). Detailed pathological data 
on stage, the presence of metastasis and Gleason grade, where available, was also 
documented upon review of case notes. All tumour sections were then made anonymous 
by removal of patient identification including hospital and pathology numbers. Each 
tissue section was subsequently assigned a number, for coding purposes. Time to 
biochemical relapse, time to death from relapse and overall sui'vival times were 
calculated from the date of diagnosis to the date of death (where available) or date of last 
follow-up (censored obseiwations). The proportion of patients surviving was then 
calculated according to the method of Kaplan-Meier and any significant differences were 
identified using the log rank test. Furthermore, in order to determine correlations with 
MAP kinase pathway, data on PSA, AR, HER2, EGFR, and AP-1 expression were also 
made available for each tumour specimen from previous work carried out in the 
laboratory on the same tissue cohort.
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Figure 1.
Example PSA profile for patient illustrating points where tumour samples were 
retrieved.
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2.2 PREPARATION OF TISSUE SECTIONS
Formalin-fixed tissue embedded in paraffin blocks, was retrieved from the archives. Prior 
to sectioning, tissue blocks were cooled to -lO'^C (Tissue Tec® cooler). Four to Five 
micrometer thick sections were then cut from the blocks using a Leica® RM 2135 
microtome. Ribbons of cut sections were then floated onto a waterbath, heated to 45°C, in 
order to flatten out any tissue folds (leading to artefacts), before application onto 
aminopropyltriethoxysilane-treated (sialinised) slides. Slides (BDH 1.0mm thick, clear 
glass) were sialinised in order to create greater adherence with the tissue, according to the 
following protocol:
• Slides placed in acetone for 5 minutes, followed by 2% silane (v/v 8ml in 
400ml acetone).
• Slides then washed in running tap water for 5 minutes, before being bathed in 
tap water for a further 20 minutes, before dried overnight in a fume hood.
Sections were then ready for immunohistochemieal staining (see Section 2.5)
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2.3 CREATION OF TISSUE MICRO-ARRAYS (TMAs)
2.3.1 INTRODUCTION
Tissue micro-aiTays (TMAs) are a well-recognised method facilitating the rapid analysis 
of multiple tissue specimens (Camp et ah, 2000). In order to assess their usefulness and 
accuracy in determining protein expression in prostate cancer, TMAs of our dataset, were 
created and stained. Their histoscores were then compared and correlated with the 
standard histological scores of the corresponding full tissue sections.
2.3.1 HAEMATOXYLIN AND EOSIN STAINING
In order to identify tumour areas suitable for selection into the array, paraffin sections 
from each patient required staining with haematoxylin and eosin, using the following 
standard protocol:
• Sections dewaxed in 2 separate washes of xylene for 2 minutes each.
• Sections rehydrated in graded alcohol solutions -  2 washes of 2 minutes each in 99% 
alcohol; 1 minute wash in 90% alcohol; 1 minute in 70% alcohol -  after which the 
sections were washed in rumiing tap water.
• Sections then placed in a staining dish containing haematoxylin for 2 minutes, then 
washed in running tap water.
• Sections then destained in acid alcohol solution for a maximum of 10 seconds, before 
being washed in running tap water once again.
• Sections then placed in a staining dish containing eosin for 2 minutes, then washed in 
rumiing tap water.
• Sections then dehydrated in graded alcohol solutions in reverse, followed by 2 washes 
in xylene.
• Sections then mounted in DPX, before application of cover slips
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2.3.2 IDENTIFICATION OF TUMOUR AREAS
Areas of tumour to be cored were then confirmed by a Consultant Pathologist (KG). 
Where possible, areas were subclassified into predominantly high and low differentiation, 
based on their Gleason grade. Grade 3 (single, separate, more iiTegular glands or rounded 
masses of cribriform or papillary epithelium) was used as low, and grade 5 (almost absent, 
few tiny glands or signet ring cells) as high (Gleason, 1992). Most tumours contained a 
mixtm’e of both high and low areas of terms of tissue differentiation.
2.3.2 CONSTRUCTION OF ARRAY
Once the appropriate tumour areas were identified in each section (high and low grade 
where possible), one-millimetre tissue cores were removed from each paraffin block using 
a manual tissue arrayer (Beecher Instruments® Micro-Array Technology). Cores were 
then placed within a fresh paraffin block in order to construct an array (see Figure 2). 
Only blocks with sufficient tumour tissue arising from TURP drippings (i.e. contained 
areas substantially greater than 1mm in total) were used for TMA construction, allowing 
the return of sufficient tissue to the archives. A plan of each array was made to track the 
identity of each core by their co-ordinate position.
Five micrometer sections were then prepared as above for immunohistochemical staining 
(see Section 2.2).
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2.4 IMMUNOHISTOCHEMISTRY
2.4.1 PRINCIPLES OF IMMUNOHISTOCHEMISTRY
Protein expression was determined using immunohistochemistry. This is a semi- 
quantitative staining technique which relies on the use of specific antibodies raised 
against epitopes of protein antigens to be analysed. In this particular study, a standard 
indirect immunoperoxidase teclmique was used to stain tissue sections. Slides containing 
5 pm sections of tissue, cut from paraffin embedded tissue-blocks, require dewaxing in 
xylene and progressive rehydration through graded alcohol solutions in order to remove 
the remnant paraffin. As some cells contain endogenous peroxidase enzymes, this can 
interfere with the use of peroxidase-labelled antibodies later on during the procedure. 
Therefore treatment with hydrogen peroxide (3%) solution is required to destroy pre­
existing peroxidase within the tissue. Thereafter an antigen-retrieval process is required 
to counter the effects of formaldehyde fixatives, which react with basic amino-acids to 
form cross-links, which have the effect of masking antigen from an antibody. These 
cross-links may be removed by a variety of processes (including incubation slides in 
heated trypsinised solution or citrate buffer solution), according to the particular antigen 
under investigation, as different epitopes are affected by tissue fixation to various 
extents. Non-specific binding of antibody to protein can result in “background staining” 
which interferes with the presence of specific staining. These sites require “blocking” 
therefore with the addition of serum, usually derived from horse.
Addition of primary antibody follows. These may be polyclonal or monoclonal 
antibodies. Polyclonal antibodies, by definition, are raised from several different clones 
of plasma cells upon inoculation of protein. As a result, the antibodies produced will 
react to different epitopes on the same antigen, and can be used at low concentrations.
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However, they may also contain non-specific antibodies, leading to background staining 
-  this can be minimised upon titration to the most appropriate concentration. Monoclonal 
antibodies, produced from a single clone of B-cells, react with one specific epitope on 
the antigen, leading to less background staining. Primary antibodies are incubated to 
varying lengths of time, depending on the antibody used (e.g. from 1 hour at room 
temperature to overnight at 4°C). Following incubation with primary antibody, addition 
of a secondary antibody is required as part of an indirect method of immunostaining. 
This is a 2 stage process, and involves the use of a biotinylated secondary antibody, 
which is then linked to a peroxide enzyme-streptavidin conjugate. Streptavidin has a low 
potential for non-specific binding, resulting in more sensitive staining. Endogenous 
biotin may however result in non-specific binding of secondary antibody, which may be 
reduced by addition of a biotin block. This however was not required with the antibodies 
used in this study. Staining is achieved upon addition of the chemical 3,3-diamino- 
benzidine tetrahydrochloride, which polymerises, in the presence of peroxidase at the site 
of the antigen, to form a visible brown reaction product. Following this, nuclei are 
counterstained blue with haematoxylin and Scotts tapwater substitute. The sections are 
then dehydrated in graded alcohol solutions and cleared in xylene, before mounting in 
DPX resin-coated coverslips. The protein in the tissue sections, DPX and glass coverslips 
have a similar refractive index, producing optimal resolution when viewed under the 
microscope.
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2.4.2. IMMUNOHISTOCHEMICAL PROTOCOL
2.4.2.1 Antibodies
The specificity of all antibodies used in this study was confirmed by western blotting. 
These procedures were conducted by a PhD student within the Laboratory at the time of 
the project (LMcG).
Raf-1
Tumour protein expression of Raf-1 was assessed using a mouse monoclonal antibody 
(IgGi raised against a peptide mapping at the carboxy terminus of Raf-1 p74 of human 
origin, Cat.No.sc-7267, Santa Cruz Bioteclmology, USA) at a 1:10 concentration. The 
antibody was initially worked up in hmnan tonsillar tissue to confirm staining (as per the 
product datasheet). The most suitable concentration was then titrated using pro static 
controls.
Phosphorylated Raf-1 (serine 259)
Tumour phospho-Raf-1 expression was assessed using a rabbit polyclonal antibody 
(raised against residues surrounding phosphorylated serine 259 of human Raf-1, 
Cat.No.#9421, Cell Signaling Technology, USA) at a 1:25 concentration. The antibody 
was initially worked up in human placental tissue to confirm staining (as per the product 
datasheet). The most suitable concentration was then titrated using prostatic controls.
Phosphorylated Raf-1 (serine 338)
Tumoui' phospho-Raf-1 expression was assessed using a rat monoclonal antibody (IgG; 
raised against residues surrounding phosphorylated serine 334 - 347 of human Raf-1, 
Cat.No.#05-534, Upstate, USA) at a 1:250 concentration. The antibody was worked up
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and titrated in human pro static tissue, which is known to express phosphorylated Raf-1 i
(serine 338).
MAP Kinase (p42/44) j
Tumour protein expression of MAP Kinase was assessed using a rabbit polyclonal 
antibody (derived from the sequence of rat p42 MAP Kinase, Cat.No.#9102, Cell J
Signaling Technology, USA) at a 1:25 concentration. The antibody was worked up and 
titrated in human prostate tissue, which is known to express MAP kinase.
Phosphorylated MAP Kinase (p42/44)
Tumour protein expression of phosphorylated MAP Kinase (pMAP Kinase) was assessed 
using rabbit polyclonal antibody (raised against residues surrounding phosphorylated 
Thr202/Tyr204 of human p44 Map Kinase, Cat.No.#9101, Cell Signaling Technology,
USA), at a 1:50 concentration. The antibody was worked up and titrated in human 
prostate tissue which is known to express the phosphorylated protein (and as 
recommended by the product datasheet).
2.4.2.2. IHC Procedure
Tissue sections (5pm) were dewaxed in xylene and rehydrated through graded alcohols.
Sections were then treated with 0.3% hydrogen peroxide solution, to remove endogenous 
peroxidases, for 20 minutes. Antigen retrieval was achieved by incubating sections in 
citrate buffer solution (DAKO Cytomation, 8ml of xlO concentrate in 80 ml distilled 
water) for 20 minutes at 97°C, allowing a further 20 minutes to cool down at room 
temperature. Sections were then blocked with horse serum solution (15pi per 1ml TBS- 
buffer) for 30 minutes at room temperature, before incubation with primary antibody at 
the appropriate concentration overnight at 4°C. Negative control sections were incubated
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with an iso-type matched control antibody in which no staining was obseiwed. Positive 
control specimens (consisiting of prostatic cancer specimens not contained in the 
database) were also included in each assay. Bound antibody was visualised using a 
biotinylated secondary antibody, streptavidin-horseradish peroxidase complex (DAKO, 
UK) and 3,3’-diaminobenzidine (DAB) as chromogen (DAKO). Tissue sections were 
counter-stained with haematoxylin and dehydrated through graded alcohols and xylene.
r
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»2.5 HISTOSCORING AND DATA ANALYSIS
2.5.1 HISTOSCORING METHOD
All immunostained tumour sections were quantified blindly and independently by 2 
observers, using a weighted histoscore method at high magnification (x 400). Specific 
staining in each tissue section (cytoplasmic and nuclear depending on the antigen studied) 
was allocated 0 (no staining), 1 (weak intensity of staining), 2 (moderate intensity), or 3 
(strong intensity). The final score (maximum 300) is calculated from the sum of:
(1 X % weak staining) + (2 x % moderate staining) + (3 x % strong staining)
Histoscore analysis therefore provides a semi-quantitative classification of staining 
intensity (Fraser et ah, 2003) (Edwards et ah, 2003a),
2.5.2 STATISTICAL TESTS
Statistical analysis was performed using Microsoft Excel and the SPSS statistical package 
(version 9.0).
2.5.2.1 Inter-Observer Variation
Interclass correlation coefficients (ICCC) were used to assess inter-observer variation of 
histoscores (Cicchetti and Sparrow, 1981). In doing so, it compares and quantifies the 
variability between observers for each section to the overall variation in all scores. ICCC 
values less than 0.4 is regarded as poor, 0.4-0.59 fair, 0.6-0.74 good, and 0.74 and above 
excellent.
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Initially every slide was double scored by an independent observer. After initial 
calculation of ICCC for Raf-1 expression, yielded scores greater than 0.9, which is classed 
as excellent, it was decided to reduce this to every tenth slide.
In addition, Pearson co-efficients, Scatter plots and Bland-Altman graphs were also 
calculated to confirm low inter-observer variation and the absence of a bias between 
scorers therefore further validating the results.
I 2.5.2.2 Protein Expression and Correlation
Protein expression data was not normally distributed and is shown as median and inter 
quartile ranges. Wilcoxon Signed Rank Tests were used to compare expression between 
ASPC and AIPC tumours. Significant changes (rising or falling) in protein expression 
between paired ASPC and AIPC tumours were defined as the mean (absolute) inter- 
obseiwer variation plus 2 standard deviations of all sections scored.
Correlations (non-linear) between proteins were calculated using the Spearman Rank 
10 Test. All p values were 2-tailed and significance was defined as p values less than or
equal to 0.05.
Time to relapse and survival analysis was conducted using the Kaplan-Meier method and 
curves were compared with the log-rank test.
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RESULTS AND DISCUSSION
82
3.1 Patient Database
A patient cohort of 65 matched androgen sensitive and insensitive prostate tumours (130 
tumours) was used in the study. The median age of the patient cohort was 70 years and 
median time of follow-up was 4.5 years. Median time to biochemical relapse was 2.5 
years and median time to death from relapse was 1.4 years. Patients in the cohort were 
diagnosed with locally advanced (46 patients) or metastatic (19 patients) prostate cancer 
and subsequently received surgery and/or androgen deprivation therapy (27 orchidectomy, 
59 GnRH analogue and/or anti-androgen therapy). Forty-six of the patients in the cohort 
died during the course of follow-up and 19 are still suiviving at last follow-up. Table 1 
shows a summary of the clinical information available for this patient cohort. A more 
detailed representation of the clinical, pathological and biochemical data from all patients 
in the study (including PSA profiles) can be found in Appendix 1.
The presence of métastasés at diagnosis was associated with a reduced time to 
biochemical relapse in this cohort (p=0.037) and a trend was seen with overall patient 
suivival (p=0.06). High Gleason score was associated with reduced time to biochemical 
recurrence (p=0.002), death from biochemical recurrence (p=0.02) and overall suivival 
(p=0.001). These results are consistent with our understanding of the clinical parameters 
associated with the progression of prostate cancer and therefore validate the use of the 
database in this study.
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Table 1. Summary of clinical characteristics of patient cohort
Diagnosis Relapse Years
Median Age (inter­
quartile range)
70 (66-74) 72 (67-78) Median time to 
biochemical relapse 
(inter quartile range)
2.54
(1.51-4.62)
No. of patients alive
No. of patients with 
metastasis
65
19
19
40
Time to death from relapse 
(inter quartile range)
1.37
(0.82-2.69)
Median Gleason 
score
8 (7-9) 8 (8-9) Overall survival 
(inter quartile range)
4.5
(3.00-7.01)
Patients undergone 
Surgical orchidectomy
27 -
Patients received 
GnRH analogue
48 -
Patients receiving 
Anti-androgen
43 -
Patients receiving 
GnRH and/or Anti­
androgen
59
84
& 3.1.1 Definition of Androgen-Sensitive (ASPC) and Insensitive (AIPC) Prostate 
Cancer
Androgen-sensitive tumour samples were taken from either TRUS biopsies or TURP 
specimens at diagnosis and prior to commencement of therapy. Thereafter, patients 
required a successful biochemical response, as demonstrated by a significant reduction in 
PSA levels (of at least 50%) in response to androgen deprivation therapy to be classified 
as ASPC in the study. Some patients at dianosis were in the pre PSA era, however they 
had histological confirmation of disease (see Appendix 1). As such, patients were 
androgen or hormone-naïve (see Materials and Methods). A truer reflection of 
androgen-sensitive specimens may have been achieved from samples taken during 
therapy with a confirmed PSA at nadir. As a result an earlier immunohistochemical 
“snapshot” of what is occurring at a molecular level. One could speculate that different 
associations may have been seen, reflecting changes en route to androgen-escaped 
disease. The availability of such samples are generally rare in clinical practice, unless a 
TURP has been performed.
Androgen-insensitive or androgen-escaped prostate cancer can be defined as biochemical 
and/or clinical disease progression during androgen-deprivation therapy with castration 
levels of serum testosterone (Hernes et al., 2004). Retrieval of AIPC tissue was from the 
pathological archives (obtained following channel TURP for subsequent bladder outlet 
obstruction). Samples were thought to be indicative of AIPC if a sustained rise in PSA 
despite maximal treatment was noted, without a later decrease even with any change of 
therapy (see Appendix 1). Furthermore, palliative resections of the prostate are generally 
performed as a result of clinical disease progression.
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The expansion of a matched patient database was a major advantage and indeed a unique 
feature of this study. The use of samples, taken sequentially from the same patient before 
androgen-deprivation therapy (ASPC) and after biochemically confirmed androgen- 
insensitive disease (AIPC), allowed tracking of the changes associated with its’ 
development (see Appendix 1). As a result, the database can play a crucial role in 
unravelling the molecular mechanisms that underlie androgen-insensitive prostate cancer.
Investigations into the clinical role of signal transduction pathways in the progression to 
AIPC has been hindered in the past by the lack of clinical material, as these patients do 
not undergo routine biopsies (Craft et ah, 1999). Discrepancies sometimes occur (for 
example in studies of HER2 expression) when radical prostatectomy specimens are used, 
as they generally contain localised disease which is not androgen-insensitive (Craft et ah,
1999). The current study, however, was a dynamic, comparative analysis of the overall 
change in protein expression with the development of androgen-insensitive disease. In 
doing so, it was possible to identify subsets of patients who demonstrated rising, falling, 
or no change in expression of members of the Raf/MAP Kinase pathway.
It could be argued that as only patients who survived long enough to develop outflow 
symptoms, and were clinically suitable for surgical inteivention, the cohort of patients 
maybe therefore skewed in favour of those with less aggressive disease. The development 
of a prospective database, which includes 3 sets of matched biopsies in future (at 
diagnosis, during treatment, and at point of relapse) is currently underway to address this. 
Furthermore, a variety of treatment modalities were used, from surgical castration, 
various GnRH analogues and androgens, sometimes in combination. An accurate
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i assessment of individual therapies alone on the Raf/MAP Kinase pathway would be of 
interest, but could only be achieved if significant numbers of each was achieved with 
further expansion of the patient cohort.
Variability in reports with respect to levels of protein expression have always been noted, 
for example with HER2 (Solit and Agus, 2001). Whilst these may reflect methodological 
differences with immunohistochemistry (as will discussed later), they may be related to 
genetic differences in the patient populations assessed. Our cohort of patients were 
recruited from patients in central Scotland, and it may be of interest to compare results 
with similar databases in Europe or further a field. These may implicate a greater role for 
a variety of different pathways. In turn, this could influence drug development at a 
regional level and have therapeutic implications.
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3.2 Inter-observer correlations/variation
Changes (fall or rise) in protein expression were determined according to mean (absolute) 
inter-observer differences in histoscores for each protein, plus 2 standard deviations (95% 
confidence interval), as previously described and further explained before (see 
MATERIALS & METHODS). Table 2 reveals values for each protein studied 
including ICCCs and Pearson co-efficients. ICCCs were consistently higher than 0.7 and 
were therefore classed as excellent. In order to eliminate observer bias, scatter graph and 
Bland-Altman plots were drawn for each protein and are shown in Appendix 2 (Figures 
1-7).
Small changes in protein expression between paired ASPC and AIPC tumours could be 
due to random errors in the assessment of histoscores. To identify individual patients in 
whom there was strong evidence of a genuine rise or fall in protein expression, it was 
required that the change in expression exceed a thr eshold equal to mean plus two standard 
deviations of the inter-observer difference for that protein. This tlireshold was chosen 
because, if there was in reality no difference in protein expression between ASPC and 
AIPC tumours in a given patient, there would be only a 5% probability of an apparent 
difference being observed that exceeded the threshold due to random variation. This 
assumes that the mean random variation between two different observers assessing the 
same tumour is of a similar magnitude to the random variation that would affect a single 
observer assessing two different tumours with the same level of protein expression. 
Changes in protein expression in individual patients that exceeded this threshold were 
termed significant.
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Mean inter­
observer 
difference
Mean + 2 
standard 
deviations
Inter class 
correlation co­
efficient
Pearson co­
efficient 
(r  ^from graph)
Raf-1 19.0 49.6 0.91 0.91
(0.83)
pRaf (ser259) 25.7 66.8 0.86 0.84
(0.71)
pRaf (ser338) 21.6 65.9 0.91 0.91
(Nuclear) (0.83)
pRaf (ser338) 14.9 45.9 0.96 0.96
(Cytoplasmic) (0.92)
MAP Kinase 9.3 28.1 0.95 0.95
(Nuclear) (0.91)
MAP Kinase 10.7 32.5 0.92 0.92
(Cytoplasmic) (0.84)
pMAP Kinase 17.2 41.2 0.94 0.95
(Nuclear) (0.90)
pMAP Kinase 15.7 41.4 0.91 0.90
(Cytoplasmic) (0.80)
Table 2. Mean inter-observer difference, Mean + 2 standard deviation, inter -class
correlation co-efficients and Pearson co- efficients for each protein 
studied.
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3.3 Immunohistochemistry
3.3.1 Raf-1 Im m unohistochem istry
Raf-1 staining was seen exclusively in the cytoplasm. Examples of immunohistochemical 
staining for Raf-1 can be seen in Figures 1.
Figure 1. Exam ple o f im m unohistochem ical staining for Raf-1.
X 4 0 0
When median Raf-1 protein expression in ASPC tumours was compared with AIPC
tumours, no statistically significant change was observed (p=0.74) (Table 3, Figure 2
below). 300
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Figure 2. Median Raf-1 histoscores for ASPC and AIPC tumours, with p value as 
assessed by Wilcoxon Signed Ranks Test.
However a subgroup analysis revealed that 17% (11/65) of cases had a significant rise in 
Raf-1 expression with development of AIPC (as measured by a rise of greater than 49.6 
histoscore units), while the remainder (54/65) demonstrated no significant rise or a fall in 
Raf-1 expression (see Table 3 and Figure 3 below).
Patients w hose Raf-1 expression rose with the developm ent of AIPC
250
200
a>oo
o»
X
100
50
ASPC AIPC
Figure 3. Changes in Raf-1 expression with the development of AIPC
In summary no significant increase in median Raf-1 expression was obseiwed in the 
transition from ASPC to AIPC, however changes in expression were obsei’ved for 
individual patients (Table 3).
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» Table 3. Raf-1 histoscores in androgen-sensitive and androgen-insensitive tumours.
ASPC AIPC P % % %
value Fall Unchanged Rise
Raf-1 135
(102.5-182.5)
137.5
(110-171.5)
0.74 20
(13/65)
63
(41/65)
17
(11/65)
Table 3 shows median histoscores and interquartile ranges for Raf-1. P values, as 
assessed by the Wilcoxon Signed Ranks Test, were used to determine any significant 
change in histoscore between ASPC and AIPC. A further subanalysis was made to 
identify groups of patients, whose expression levels fell, rose or remained unchanged 
between ASPC and AIPC (depending on changes within or outside the 95% 
confidence interval for inter-observer variation).
ASPC, androgen-sensitive prostate cancer ; AIPC, androgen-insensitive prostate cancer.
3.3.2 Phospho-Raf (serine 259 and serine 338) Immunohistochemistry
Inactive phosphorylated Raf, pRaf (ser259), staining was seen exclusively in the peri 
membranous region of the cell whilst activated phosphorylated Raf, pRaf (ser338), was 
seen in the cytoplasm and nucleus (which were given individual histoscores). Examples 
can be seen in Figures 4 and Figure 5 below.
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Figures 4. Exam ple o f im m unohistochem ical staining for pR af (serine 259).
X 4 0 0
Figures 5. Exam ple o f im m unohistochem ical staining for pR af (serine 338).
X 4 0 0
The total number of paired specimens analysed were 65 for pRaf (ser259> and 50 for 
pRaf (ser338). There was no statistically significant increase in protein expression for 
pRaf (ser259) (p=0.42) or pRaf (ser338) (p=0.22 and 0.43 for nuclear and cytoplasmic 
expression respectively) associated with the development of AIPC (see Table 4 and 
A ppendix 3 - Figure 13a,b,c). However a subgroup analysis once again revealed that 
protein expression in individual tumour pairs either rose, fell, or remained unchanged 
after escape.
In 18% (12/65) of cases, there was a significant rise in pRaf (ser259) expression with 
development of AIPC (corresponding to a rise of greater than 66.8 histoscore units).
while the remainder demonstrated no significant change or a fall in expression (see 
Table 4 and Appendix 3 - Figure 14a).
In the case of nuclear and cytoplasmic pRaf (ser338), a significant rise was noted in 30% 
(15/50) and 28% (14/50) of cases respectively (corresponding to a rise of greater than 65 
and 45 histoscore units respectively). The remainder demonstrated no significant change 
or a fall in expression (see Table 4 and Appendix 3 - Figure 14b).
Table 4. Protein histoscores for phosphorylated Raf in ASPC and AIPC tumours.
ASPC AIPC P
value
%
Fall
%
Unchanged
%
Rise
pRaf 127.5 137.5 0.42 14 69 17
(ser259) (105-160) (89-175) (9/65) (45/65) (11/65)
pRaf 55 50 0.22 16 54 30
(ser338)
nuclear
(0-125) (0-200) (8/50) (27/50) (15/50)
pRaf 100 92.5 0.43 32 40 28
(ser338)
cytoplasmic
(20-114) (23 -103) (16/50) (20/50) (14/50)
Table 4 shows median histoscores and interquartile ranges for activated and inactivated 
phosphorylated Raf expression. P values, as assessed by the Wilcoxon Signed Ranks Test, 
were used to assess any significant change in histoscore between ASPC and AIPC tumours. A 
further subanalysis was made to identify groups of patients, whose expression levels fell, rose
94
remained unchanged between ASPC and AIPC (depending changes within or 
outside the median plus 95% confidence interval for inter-observer variation). 
pRaf (ser259), inactivated, phosphorylated Raf-1. 
pRaf (ser338), activated, phosphorylated Raf-1.
ASPC, androgen-sensitive prostate cancer ; AIPC, androgen-insensitive prostate 
cancer.
3.3.3 MAP Kinase / Phosphorylated MAP Kinase Immunohistochemistry
MAP Kinase expression (total and phosphorylated) was present in both cytoplasm and 
nucleus (and given individual histoscores) (see Figure 6 and 7).
Figures 6. Example of immunohistochemical staining for MAP Kinase.
X 4 0 0  
7
Figures 7. Example of immunohistochemical staining for activated phosphorylated 
MAP Kinase (pMAP).
X 4 0 0
The total number of paired specimens analysed was 56. There was no statistically 
significant increase in nuclear or cytoplasmic expression of MAP Kinase nor its’ active 
phosphorylated form (pMAP Kinase), with the development of AIPC (Table 5 and 
Appendix 3 - Figures 15 and 16). Once again, sub-groups of tumours rose, fell, or 
remained unchanged with the development of AIPC. Nuclear and cytoplasmic expression 
of MAP kinase rose in 34% and 23% of patients respectively (19/56 and 13/56 patients) 
and in 27% and 26% of patients in the case of pMAP kinase (15/56 and 11/56 patients) 
(see Table 5 and Appendix 3 - Figures 17 and 18).
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Table 5, MAP Kinase protein histoscores in ASPC and AIPC tumours.
ASPC AIPC p value %
Fall
%
Unchanged
%
Rise
MAP Kinase 60 80 0.27 27 39 34
(Nuclear) (20-100) (30-100) (15/56) (22/56) (19/56)
MAP Kinase 150 160 0.52 18 59 23
(Cytoplasm) (120-190) (130-190) (10/56) (33/56) (13/56)
pMAP 90 90 0.82 23 50 27
Kinase
(Nuclear)
(32-144) (52-119) (13/56) (28/56) (15/56)
pMAP 120 120 0.93 20 60 20
Kinase
(Cytoplasm)
(76-160) (92-150) (11/56) (34/56) (11/56)
Table 5 shows median histoscores with interquartile ranges for MAP Kinase expression and 
its’ activated, phosphorylated form, pMAP Kinase. P values, as assessed by the Wilcoxon 
Signed Ranks Test, were used to assess any significant change in histoscore between ASPC 
and AIPC. A further sub analysis was made to identify groups of patients, whose expression 
levels fell, rose or remained unchanged between ASPC and AIPC
pMAP Kinase, activated, phosphorylated MAP Kinase ; ASPC, androgen-sensitive prostate 
cancer ; AIPC, androgen-insensitive prostate cancer.
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3.4 Discussion of Raf-1 and MAP Kinase Protein Expression
3.4.1 Use of Immunohistochemistry in Assessing Protein Expression
Any demonstration of a functional pathway in vivo may be more accurate when based on 
actual protein expression, rather than gene amplification or mRNA expression. Gene 
amplification does not always result in increased protein expression and certainly does 
not provided any information on the activation status of the protein. In support of this, 
HER2 amplification is not associated with protein overexpression in prostate cancer 
(Bartlett et al., 2005). Similarly mRNA is subject to various external influences before 
final translation into a functional protein. Over expression of c-myc mRNA has been 
noted in prostate cancer tissue homogenates, but mRNA and protein was not 
overexpressed when using actual tissue sections (Karayi and Markham, 2004). To this 
effect, immunohistochemistry was selected as the primary mode of determining extent 
and pattern of protein expression.
However there are inlierent difficulties associated with the technique of IHC. One of the 
main concerns regarding IHC as a technique relates to inconsistency of repoits in the 
literature. Inconsistency of results may relate to various factors such as use of different 
reagents, differences in tissue-processing techniques (including fixation and antigen- 
retrieval), and the use of antibodies with different sensitivities and specificities (Solit and 
Agus, 2001). Studies of HER2 expression in prostate cancer, for example have revealed 
conflicting results due to varying sample size, and methodological variation, not just in 
terms of antibodies used but also the techniques used in determining degree of expression 
(Karayi and Markham, 2004).
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It has also been suggested previously that IHC can also be limited in determining protein 
expression levels due to the semi-quantitative nature of scoring techniques (Linja et ah, 
2001). Furthermore, the use of grading systems in breast cancer may not be as useful in 
prostate cancer, which may explain the lack of predictive value as yet for HER2 
expression in prostate cancer (Solit and Agus, 2001). With the inherent subjectivity 
associated with IHC, the use of a standardised grading scale for protein quantification is 
required if prognostic or therapeutic implications can be drawn from IHC based studies in 
prostate cancer (Solit and Agus, 2001).
Despite these known limitations, analysis of protein expression by IHC is central to 
current diagnostic pathology and friture clinical therapies based on translational research 
(Bartlett et al., 2001). Its’ use as a diagnostic and experimental tool is expanding, as 
demonstrated by the emergence of Herceptin® test in metastatic breast cancer (Bartlett et 
al., 2001). Diagnostic evaluation using IHC commonly involves the use of a histoscoring 
technique. We employ a weighted histoscore, which translates the histoscore into a 
continuous variable (Kirkegaard et al., 2005). Although IHC can only ever be semi 
quantitative due to the nature of the technique, use of the weighted histoscore goes some 
way to address the problems associated with determining levels of protein expression as a 
continuous variable. The accuracy of this method is dependent on limiting subjective 
inter-obseiwer variation. This can be achieved in a research setting (regardless of tumour 
type and sample size) if sections are dual scored by trained independent observers 
(Kirkegaard et al., 2005). Once a high standard of consistency and reproducibility is 
achieved, it has been demonstrated that dual scoring may be reduced to 10% of samples 
without resulting loss of accuracy (Bartlett et al., 2001) (Kirkegaard et al., 2005). Quality 
assurance and standards of inter-observer variation can be accurately quantified
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statistically by calculation of inter-class correlation co-efficients (Cicchetti and Sparrow, 
1981) (Kirkegaard et al., 2005). The ICCCs in this study were consistently greater than 
0.86, which is classified as ‘‘excellent” under current criteria. This validates our 
histoscoring technique to the extent that any correlations can be deemed accurate. The 
study further demonstrates the potential reliability and validity of weighted histoscoring 
when used in a specialised laboratory using the same blinded obseiwers.
However, protein expression itself does not equate to protein activation (Gioeli et ah, 
1999) (Mandell, 2003). The use of phospho- and activation-state specific antibodies is 
well described and may provide a means by which the activation status of signal 
transduction pathways can be demonstrated at a histological level (Gioeli et al, 1999). 
Although other studies have demonstrated expression and activation of MAP Kinase in 
human tumours, these have used immune-complex assays on tissue homogenates which 
include non-cancerous cells (Ito et a l, 1998) (Magi-Galluzzi et a l, 1997). To date 
therefore, this is the largest study to demonstrate immunohistochemical activation of the 
Raf/MAP Kinase pathway in clinical prostate cancer specimens.
As one would expect, variability exists in the expression of phosphorylated proteins when 
compared to total protein expression (Bacus et a l, 1996). In support of this, total MAP 
Kinase expression was not associated with its’ phosphorylated form in one study in direct 
contrast to ours (Gioeli et al, 1999). In this study, significant associations were 
sometimes demonstrated between total expression of protein but not activated forms (such 
as between the activated forms of Raf-1 and MAP Kinase). This may be a result of the 
reduced time each protein exists in its’ activated state due to rapid deactivation, 
particularly Raf-1. As a result, tissue sections stained with phosphorylated antibodies
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portray a “snapshot” of activation state at the moment sampling of tissue took place. Lack 
of correlations may reflect inherent difficulties with the use of antibodies directed against 
phosphorylated proteins, and to this effect total expression of Raf-1 and MAP Kinase is 
still highly valuable and may sometimes be a more reliable indicator. Alternatively, cross- 
immunoreactivity for phosphorylated antibodies may account for some of the loss of 
correlations.
3.4.2 Localisation of Members of the MAP Kinase Pathway
All antibodies used in the current study had specificity confirmed by Western blotting. 
The immunohistochemical localisation of Raf-1 and MAP Kinase was consistent with our 
cunent understanding of the subcellular distribution of Raf and MAP Kinase following 
activation. Raf-1 is known to be expressed in both non-metastatic and metastatic prostate 
cancer cells (Weinstein-Oppenheimer et al., 2000) (Fu et al., 2003). The presence of the 
active and inactive forms of Raf-1, as demonstrated in this study, also confirms their 
presence in prostate cancer and provides an insight into their localisation in AIPC. Raf-1 
expression in this study was seen diffusely in the cytoplasm and peri-membranous areas. 
Its’ inactivated form was seen only at the peri-membranous region, where 
phosphorylation at the serine 259 occurs. Once activated (by phosphorylation at serine 
338) at the membrane, it migrates into the cytoplasm where it targets MEK. In addition, 
activated Raf-1 is known to travel to the nucleus where it can function independently of 
the MAP Kinase pathway by targeting the retinoblastoma gene (Wang et al., 1998). 
However total Raf-1 expression was not consistently seen in the nucleus possibly due to 
the antibody being less sensitive.
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Once phosphorylated in the cytoplasm MAP Kinase migrates to the nucleus (Gioeli et ah, 
1999). In the current study intense staining for total and activated MAP Kinase was 
present in the nuclei as well as the cytoplasm of neoplastic epithelium. Adjacent, non- 
cancerous epithelium revealed little or no staining for total and activated MAP Kinase, 
although staining was present in surroimding smooth muscle stroma and endothelium 
consistent with previous work by Gioeli et al. 1999 (Gioeli et al., 1999). However, unlike 
Gioeli et el. 1999, we also observed marked expression for phospho-MAP Kinase in 
lymphocytic aggregates.
In conclusion, using immunohistochemistry we observed protein expression of total and 
phosphorylated Raf-1 and MAP Kinase in areas consistent with those reported in 
current literature. The specificity of antibodies used in this study were previously 
confirmed by Western blotting. This combined with the localisation of the protein 
expression suggests that staining obseiwed was specific for Raf-1 and MAP Kinase.
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3.5 The Role of the Raf/MAP Kinase Pathway in the Development of 
Androgen-Insensitive Prostate Cancer -  Impact on Time to Relapse and 
Survival
3.5.1 Raf-1 and phosphorylated Raf (serine 259 and serine 338)
When Raf-1 histoscores were divided by median, no conelation was seen (Kaplan-Meier 
analysis) between high histoscores (above median) and time to relapse, although a trend 
was seen for shortened relapse time and Raf-1 histoscores below the median (1.9 years vs 
3.4 years, p=0.07. Figure 8a and Appendix 4 - Table la).
Figure 8a
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Kaplan-Meier plot for patients with high Raf-1 expression (above the median 
histoscore) in ASPC tumours, compared to those with low expression. There was no 
significant difference in time to relapse in these patient subgroups (p=0.07), 
although a trend was seen.
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Patients whose Raf-1 expression rose with the development of AIPC, however, had a 
significantly shorter time to relapse than those patients who had a fall or no change 
(p=0.0005, see Figure 8b). Time to relapse in those patients with a rise in Raf-1 
expression was 1.16 years (1.12 years - 1.20 years) compared to 2.62 years (1.52 years - 
3.70 years) for those who had a fall or no change in Raf-1 expression (see Appendix 4 - 
Table lb).
Figure 8b.
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Kaplan-Meier plot for patients who demonstrated a rise in Raf-1 expression with 
the development of AIPC, compared to those that did not. There was a significant 
difference in time to relapse in these patient subgroups (p = 0.0005).
There was no association between Raf-1 expression and time to death from relapse, and 
overall survival (see Appendix 4 ~ Tables 2 and 3).
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Whilst there was no correlation between pRaf (ser259) expression in the primary 
tumours and time to relapse, there was a trend seen between patients whose pRaf 
expression rose with the development of AIPC and a shorter time to death from relapse 
(0.83 years vs 1.87 years, p=0.08, see Figure 9a and Appendix 4 - Table 2b). pRaf 
(ser259) expression did not influence overall survival however (see Appendix 4 -  Table 
3).
Figure 9a.
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Kaplan-Meier plot for patients who demonstrated a rise in pRaf (ser259) expression 
with the development of AIPC, compared to those that did not. There was a trend 
for shortened time to death from relapse in these patient subgroups, although this 
was not significant (p = 0.08).
No correlations were seen between pRaf (ser338) expression when divided according to 
median and time to relapse, death from relapse and overall survival. Similarly, no
105
coiTelations were seen when subgroups of patients with rising expression with the 
development of AIPC (see Appendix 4 -  Tables 1, 2 and 3). Interestingly, unlike any 
of the other proteins analysed in the study, a distinct association was seen between time 
to prolonged biochemical relapse when nuclear expression fell. The median time to 
relapse in patients with falling nuclear pRaf (ser338) expression with the development 
of AIPC was 4.6 years (3.4 years to 5.8 years) compared to 2.2 years (1.84 years to 2.56 
years) for patients whose levels remained unchanged or rose (p=0.01, see Figure 9b 
and Appendix 4 - Table lb).
Figure 9b
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Kaplan-Meier plot for patients who demonstrated a significant fall in pRaf (ser338) 
expression with the development of AIPC, compared to those that did not. There was 
a significant difference in time to relapse in these patient subgroups (p = 0.01).
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3.5.2 MAP Kinase and pMAP Kinase expression
When MAP Kinase and pMAP Kinase histoscores were divided by median, no 
correlation was seen (Kaplan-Meier analysis) between high histoscores (above median) 
and time to relapse. However a trend was seen for increased time with high nuclear (2.62 
years vs 2.13 years, p=0.06) and high cytoplasmic pMAP Kinase expression (2.98 years 
vs 2.29 years, p=0.08). (see Appendix 4 - Table 4a).
When histoscores were divided into patients whose expression rose with development of 
AIPC and those that did not, once again there was no correlation seen, although a trend 
was seen for shorter time to relapse with a rising cytoplasmic expression of pMAP 
Kinase (2.25 years vs 2.62 years, p=0.06). (see Appendix 4 - Table 4b).
MAP Kinase expression and Survival Time
There was no correlation seen between time to death from relapse and overall survival 
with MAP Kinase and pMAP Kinase expression when divided according to median 
(ASPC and AIPC) (see Appendix 4 - Tables 5a and 6a). Patients whose nuclear MAP 
Kinase expression rose with the development of AIPC did however have a significantly 
shorter time to death from relapse compared to those that had a fall or no change in 
expression (1.40 years (1.20 years - I.6I years) vs 3.00 years (1.43 years -  4.57 years), 
p=0.0255) (see Figure 10a and Appendix 4 - Table 5b). This translated into a shorter 
overall suiwival (3.37 years (1.58 years -  5.16 years) vs 6.89 years (5.70 years -  8.08 
years), p=0.0068) (see Figure 10b and Appendix 4 - Table 6b).
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Kaplan-Meier plot for patients who demonstrated a rise in nuclear MAP Kinase 
expression with the development of AIPC, compared to those that did not. There 
was a significant difference in in time to death from relapse in these patient 
subgroups (p = 0.0255) and overall survival in these patient subgroups (p = 
0.0068).
3.5.3 The Impact Raf/MAP Kinase Pathway on Time to Relapse and Survival -  A 
Prognostic Indicator?
The data from this study revealed that expression levels in ASPC and AIPC were not 
individually significant. However changes in protein expression (rise or fall) were more 
clinically relevant as correlations affecting time to relapse and overall survival were 
demonstrated using Kaplan-Meier analysis. In the case of nuclear pRaf (ser338) falling 
expression versus non-fallers (rising expression and no change combined) also appeared 
to be significant and a separate analysis was therefore performed.
Raf-1
Eleven patients (17%) showed a significant increase in the mean Raf-1 histoscore in 
AIPC. Patients with elevated Raf-1 expression at relapse demonstrated a reduction of 1.46 
years in time to biochemical relapse - a fall of greater than 50% (p = 0.0005). This data 
would suggest, as we hypothesised, that an increase in Raf-1 expression leads to a more 
aggressive and rapid disease progression to AIPC. In the current study this association did 
not, however, translate into altered overall survival. Since only 63% (24/65) of patients 
were dead at time of follow up, and 5 out of 11 of these were included in those with a rise 
in Raf-1 expression, this study maybe insufficiently powered to demonstrate a significant 
difference in overall suiwival.
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It was also observed that those with low Raf-1 expression (above tbe median) also bave 
reduced time to relapse (p=0.07). Tbis may be due to patients witb rising Raf-1 
expression having low expression at the androgen-sensitive stage. It would appear that the 
increase in Raf-1 occumng with relapse (which is associated with low initial expression) 
leads to a more aggressive disease progression. High initial expression of Raf-1, 
conversely, is in fact associated with more stable disease. Its’ ability to predict time to 
relapse, migbt enable it to act as a potential prognostic marker.
No correlations were seen witb rising expression of activated Raf. As mentioned earlier 
however, when patients with rising expression of nuclear pRaf (ser338) were combined 
with those who demonstrated no significant change (non-fallers), there was a significantly 
lower time to biochemical relapse (by 2.4 years) when compared to patients who 
demonstrated a fall in expression. This would still be consistent witb the findings of total 
Raf-1.
A trend was noted with shorter time to death from relapse in AIPC when levels of the 
inactive form of Raf-1 (ser259) rose (p=0.08). This may be explained by tbe negative feed 
back loop that exists to control Raf-1 activation via MAP Kinase i.e. activation of Raf-1 
subsequent leads to inactivation and therefore an increase in levels of pRaf (ser259) 
(Rushworth et al., 2005). To support this we would predict rising MAP Kinase to also 
influence time to death from relapse and correlations to be seen between its’ expression 
and pRaf (ser259). Tbis proved to be the case (see below).
MAP Kinase
15 patients (27%) demonstrated a rise in nuclear expression of MAP Kinase witb the 
development of AIPC, and subsequently developed a significantly shorter time to death
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from relapse, by 1.6 years, compared to tbose tbat had a fall or no change In expression 
(p=0.02). This translated into a reduction in overall survival by 3.5 years (p=0.0068).
Interestingly, there was also an association seen between rising cytoplasmic pMAP 
Kinase expression and reduced time to biochemical relapse (by 0.38 years, p=0.06). 
There was also an association with low cytoplasmic and nuclear pMAP Kinase expression 
at diagnosis (ASPC) and reduced time to relapse (by 0.71 and 0.50 years, p=0.08 and 
p=0.06 respectively). Whilst these were not significant, their trend was consistent with our 
previous findings albeit witb a more modest reduction in time. As with Raf-1, it would 
appear tbat increasing protein expression irrespective of the actual initial level at 
diagnosis or at the androgen-insensitive stage, is a more significant clinical parameter.
In summary, our results implicated elevated expression of members of the MAP Kinase 
pathway in a more aggressive and rapid disease process, with the development of AIPC. 
Whilst a rise in Raf-1 expression leads to a quicker biochemical relapse, rising 
expression of MAP Kinase impacts directly on time to death from relapse and overall 
patient survival thereafter.
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3.6 The Role of the Raf/MAP Kinase Pathway in the Development of 
Androgen-Insensitive Prostate Cancer — Raf-1 and MAP Kinase Protein 
Correlations
3.6.1 Correlations between Raf-1 and its’ phosphorylated forms
Whilst Raf-1 correlated weakly with its’ inactivated form, pRaf (ser259), before relapse 
(p=0.028), a stronger correlation was seen after the development of AIPC (p=0.008) (see 
Table 6a). No correlations were seen between Raf-1 witb tbe cytoplasmic expression of 
its’ activated form, pRaf (ser338).
Table 6a. Correlation between Raf-1 and pRaf (serine 259 and 338) expression 
before and after AIPC.
pRaf (ser259) pRaf (ser338) cytoplasmic
Raf-1 (ASPC) 0.028 (0.27) 0.971 (0.05)
Raf-1 (AIPC) 0.008 (0.32) 0.445 (-0.10)
Tables 6a shows significant correlations (p values) between Raf-1 and its’ 
phosphorylated forms in ASPC and AIPC tumours. Correlation coefficients are 
shown in brackets. P values were assessed by Spearman’s Rank Correlation Test.
Protein expression of tbe inactive form of pRaf (ser259) and tbe active form of pRaf 
(ser338) in tbe cell cytoplasm did not correlate in ASPC or AIPC (p=0.35 and p=0.96 
respectively). However, the nuclear and cytoplasmic forms of pRaf (ser338) strongly 
correlated with each other in ASPC (p=0.01) and AIPC tumours (p<0.001) (see Table 
6b)
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Table 6b. Correlation between pRaf (serine 259 and 338) expression before and after 
AIPC.
pRaf (ser338) cytoplasmic
pRaf (ser338) nuclear (ASPC) 0.01 (0.34)
pRaf (ser338) nuclear (AIPC) <0.001 (0.74)
Tables 6b shows significant correlations (p values) between the Cytoplasmic and 
nuclear forms of activated Raf-1 -  pRaf (ser338) -  in ASPC and AIPC tumours. 
Correlation coefficients are shown in brackets. P values were assessed by 
Spearman’s Rank Correlation Test.
3.6.2 Correlations between MAP Kinase and its’ phosphorylated form
Significant correlations were seen between tbe cytoplasmic and nuclear expression of 
MAP Kinase and activated, phosphorylated MAP Kinase (pMAP Kinase) in ASPC and 
AIPC tumours individually (Appendix 5 - Tables 7a and 7b).
In ASPC tumours, cytoplasmic expression of MAP Kinase correlated with its’ nuclear 
expression (p=0.013) as well as the cytoplasmic expression of its’ activated form 
(p<0.001). Nuclear MAP Kinase expression in addition correlated very strongly with its’ 
activated form in the nucleus (p<0.001). Activated MAP Kinase in the cytoplasm was 
also very strongly associated with its’ activated expression in the nucleus (p<0.001). A 
summary can be seen in Figure 11a.
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Figure l ia  -  Fiow diagram summarising MAP Kinase correlations in ASPC 
tumours.
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After the development of AIPC, cytoplasm expression of MAP Kinase became strongly 
associated witb its’ expression in the nucleus (p=<0.001) but no longer correlated anymore 
with its’ activated form in the nucleus. Cytoplasmic expression of MAP Kinase still correlated 
with its’ activated form in the cytoplasm (p=0.010), which remained strongly associated witb 
tbe activated form in the nucleus (p<0.001). A summary can be seen in Figure 11b.
Figure 11b. Flow diagram summarising MAP Kinase correlations in AIPC tumours.
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3.6.3 Correlations between Raf-1 and MAP Kinase
In ASPC tumours, Raf-1 and its’ inactive form, pRaf, correlated witb the cytoplasmic 
expression of MAP Kinase (p=0.002 and p=0.003 respectively), and activated MAP 
Kinase (p=0.002 and p=0.049 respectively). Raf-1 also coiTelated with nuclear activated
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MAP Kinase (p=0.003). There were no correlations seen between pRaf (ser338) and
MAP Kinase or pMAP Kinase (see T able 7a).
Table 7a. Correlations between Raf-1 and MAP Kinase in ASPC tumours
Raf-1 pRaf (ser259) pRaf (ser338)(cyto)
MAP Kinase 0.319 0.441 0.280
(nuclear) (0.13) (0.10) (-0.16)
MAP Kinase 0.002 0.003 0.826
(cytoplasm) (0.40) (0.39) (0.03)
pMAP Kinase 0.003 0.431 0.221
(nuclear) (0.38) (0.11) (-0.17)
pMAP Kinase 0.002 0.049 0.982
(cytoplasm) (0.40) (0.26) (0.00)
Tables 7a shows correlations (p values) between Raf-1, inactive and active 
phosphorylated Raf, and the nuclear and cytoplasmic expression of MAP Kinase, and 
its’ activated, phosphorylated form. Significant correlations (p<0.05) are highlighted. 
P values were assessed by Spearman’s Rank Correlation Test. Correlation co efficients 
in brackets.
pRaf (ser259), inactive phosphorylated Raf ; pRaf (ser338) active phosphorylated Raf 
pMAP Kinase, activated phosphorylated MAP Kinase
In AIPC tumours, Raf-1 was still associated with cytoplasmic and now nuclear MAP Kinase 
expression (p=0.003 and 0.007). Cytoplasmic MAP Kinase also correlated with pRaf
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(ser259) (p=0.008). There were still no correlations seen between pRaf (ser338) and MAP
Kinase (See T able 7b).
Table 7b. Correlations between Raf-1 and MAP Kinase in AIPC tumours
Raf-1 pRaf (ser259) pRaf (ser338)(cyto)
MAP Kinase 0.007 0.351 0.087
(nuclear) (0.34) (0.12) (-0.24)
MAP Kinase 0.003 0.008 0.503
(cytoplasm) (0.37) (0.33) (-0.09)
pMAP Kinase 0.355 0.204 0.949
(nuclear) (0.12) (0.16) (0.01)
pMAP Kinase 0.612 0.102 0.293
(cytoplasm) (0.07) (0.21) (-0.14)
Tables 7b shows correlations (p values) between Raf-1, inactive and active 
phosphorylated Raf, and the nuclear and cytoplasmic expression of MAP Kinase, and 
its’ activated, phosphorylated form. Significant correlations (p<0.05) are highlighted. 
P values were assessed by Spearman’s Rank Correlation Test. Correlation co efficients 
in brackets.
pRaf (ser259), inactive phosphorylated Raf ; pRaf (ser338) active phosphorylated Raf 
pMAP Kinase, activated phosphorylated MAP Kinase
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3.6.4 Raf-1 Activation -  The Role of Serine 259 and 338 Phosphorylation
The serine 259 and 338 phosphorylation sites play a crucial role in determining the 
activity and biological outcome of Raf-1 (Dhillon et ah, 2002a) (Dhillon et ah, 2002b). 
Dephosphorylation of serine 259 in response to Ras stimulation is essential for peak 
activation of Raf-1. This facilitates Raf-1 membrane translocation, enhancing its’ 
interaction with Ras, and stabilizing its’ subsequent activation by phosphorylation of 
serine 338 (Figure 12) (Dhillon et ah, 2002a) (Tzivion et ah, 1998). Re-phosphorylation 
at serine 259, thereby deactivating Raf-1, provides a regulatory feedback mechanism to 
limit Raf-1 signalling and may occur via Ras cross-talk with PKA, Akt (serine kinases 
which are known to deactivate Raf-1 at serine 259), or an as yet unknown protein kinase 
(Dhillon et ah, 2002a) (Abraham et ah, 2000). Therefore, the activation state of Raf-1 is 
complex and dynamic, and exposed to rapid turnover of phosphorylated and 
dephosphorylated states.
In this study, total Raf-1 expression coiTelated with its’ inactive form (p=0.028) in ASPC 
tumours. This correlation was strengthened in AIPC tumours (p=0.008). There were no 
correlations with its’ active form, however this is consistent with the current 
understanding of Raf-1 dynamics. Once Raf-1 is activated at serine 338, it is marked for 
immediate dephosphorylation and re-phosphorylation at serine 259 resulting in its’ return 
to the cytoplasm in an inactive and more stable state (Kubicek et ah, 2002). Direct 
protein correlations with pRaf (ser338), as noted in this study, may reflect this and 
therefore maybe difficult to interpret.
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Figure 12. Raf-1 Activation -  T he R ole o f Serine 259 and 338 Phosphorylation
3.6.5 Raf-1 A ctivation o f M AP K inase  
ASPC
Both Raf-1 and its’ inactive form, pRaf (ser259) correlated with expression o f total and 
activated MAP Kinase. Cytoplasmic MAP Kinase expression correlated with activated 
cytoplasmic MAP Kinase expression, which correlated with nuclear activated MAP 
Kinase expression (p<0.001 and p<0.001). This data suggests that Raf-1 activates MAP 
Kinase in the cytoplasm, which in turn translocates to the nucleus. No correlations were 
observed between activated Raf-1 and activated MAP Kinase, however this was not 
unexpected as Raf-1 becomes rapidly inactivated and phosphorylated at serine 259 as 
discussed above.
AIPC
With development o f  AIPC, Raf-1 was still associated with cytoplasmic and now nuclear 
MAP Kinase expression (p=0.003 and 0.007). Correlations with activated MAP Kinase
interestingly were now lost. The inactive form of Raf-1 still correlated with cytoplasmic 
MAP Kinase (p=0.008), but not with its’ activated form. Despite this, cytoplasmic MAP 
Kinase still strongly correlated with its’ activated form in the cytoplasm (p=0.01) which 
correlated with the activated form in the nucleus, so a pathway from Raf-1 to activated 
nuclear MAP Kinase was still present.
Correlations between Raf protein expression, its’ kinase activity and MEK activation is 
not always seen in vitro, implying that Raf/MAP Kinase coupling is complex, and 
carefully adjusted in cells (Dhillon et ah, 2003). It is also possible that, whilst Raf-1 
continues to activate nuclear MAP Kinase expression, the loss of some of the direct 
Raf/MAP Kinase correlations is related to an increasing degree of independent Raf-1 
function, outwith the MAP Kinase cascade, with the development of clinical AIPC (Wang 
et a l, 1998) (Figure 13). This may be supported by the fact that cytoplasmic and nuclear 
forms of activated Raf-1 strongly correlated with each other in androgen-sensitive 
(p=0.01) but even more strongly in androgen-insensitive tumours (p<0.001).
There is increasing evidence for such independent Raf-1 activity outwith the MAP Kinase 
cascade (Dhillon et a l, 2003) (Dasgupta et a l, 2004). Raf-1 can bind and inactivate the 
retinoblastoma tumour suppressor protein (Rb) directly resulting in cell cycle progression 
beyond the Gl/S barrier (Wang et a l, 1998). Raf-1 overexpression can thereby facilitate 
cellular proliferation and, as in vitro studies would suggest, vascular endothelial growth 
factor (VEGF)-induced angiogenesis, independently of MAP Kinase (Dasgupta et al,
2004). The inactivation of Rb through phosphorylation is therefore thought to play a 
significant role in carcinogenesis.
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Once stimulated, significant translocation of Raf-1 occurs from the cytoplasm into the 
nucleus, where its’ interaction with Rb, a nuclear protein, takes place (Wang et ah, 1998) 
(Dasgupta et ah, 2004), This is consistent with the immunohistochemical findings in this 
study, which demonstrated activated Raf-1 presence in the nucleus as well as cytoplasm. 
This was not seen with total Raf-1 and inactive Raf-1 presumably as Raf-1 only enters the 
nucleus when activated and its’ subsequent inactivation only occurs in the cytoplasm 
secondary to Akt or PKA. The mechanism by which Raf-1 enters the nucleus, without 
interacting with the MAP Kinase pathway, is unknown but may involve the presence of as 
yet unidentified chaperone proteins (Wang et ah, 1998). In doing so, Raf-1 may well 
directly affect other nuclear targets in addition to Rb.
Raf-driven inhibition of apoptosis has also been noted to be independent of MAP Kinase 
(Dhillon et ah, 2003) (Cox and Der, 2003). In support of this, Raf-1 can physically 
interact with the pro-apoptotic bcl-2, shifting to the mitochondria whilst bound to it and 
inactivating the pro-apoptotic protein, BAD (Wang et ah, 1998) (Cox and Der, 2003). 
Upregulation of bcl-2 has already been associated with the development of AIPC 
(Grossmann et ah, 2001) (Chen et ah, 2004).
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Figure 13. Raf-1 targets outwith the M AP K inase pathway
Raf-1 independent activity may therefore explain the loss o f some o f  the correlations in 
particular between Raf-1 and activated MAP Kinase with the development o f AIPC. This 
may imply increased dysregulation o f  the Raf/MAP Kinase pathway as a result o f cancer 
progression.
In line with these observations, high MAP Kinase expression has previously been 
observed in early stages o f  prostate cancer, correlating with cell proliferation (Uzgare et 
al., 2003). Intriguingly, the constitutively active form o f MAP Kinase also induces Raf-1 
activation in cell-line studies, forming the positive feedback loop required for chronic 
autocrine stimulation (Weinstein-Oppenheimer et al., 2000). This may explain the degree 
o f correlations seen here. The data also supports the hypothesis that stimulation o f the 
Raf/MAP Kinase pathway possibly via type 1 receptor tyrosine kinases, results in the 
elevated expression o f  activated members o f the pathway (Gioeli et al., 1999).
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3.7 Correlations with Other Proteins in the Signalling Pathway
3.7.1 Correlations with Other Proteins in ASPC Tumours
In androgen-sensitive tumours, expression of the growth factor receptor HER2 correlated 
with Raf-1 expression (p=0.019). HER2 also correlated with cytoplasmic MAP Kinase 
expression (p=0.02), and with the nuclear and cytoplasmic expression of pMAP Kinase 
(p=0.03 and p<0.001 respectively). There was a weak negative association with HER2 and 
activated pRaf (ser338) in the cytoplasm (p=0.06). Once activated, its’ phosphorylated 
form (pHER2) correlated strongly with pRaf (ser259) (p=0.001), but not the activated 
forms of Raf and MAP Kinase (see Table 8a).
Table 8a. Protein correlations between Raf/MAP Kinase and HER2 in ASPC 
tumours.
HER2 pHER2
Raf-1 0.019 (0.34)
pRaf (ser259) 0.162 (0.21) 0.001 (0.49)
pRaf (ser338) (nuclear) 0.397 (-0.14) 0.801 (0.04)
pRaf(ser338) (cytoplasm) 0.06 (-0.30) 0.824 (0.04)
MAP Kinase (nuclear) 0.292 (0.16)
MAP Kinase (cytoplasm) 0.002 (0.46)
pMAP Kinase (nuclear) 0.003 (0.45) 0.54 (-0.10)
pMAP Kinase (cytoplasm) <0.001 (0.60) 0.50 (0.11)
Table 8a shows correlations (p values) between Raf-1, inactive and active 
phosphorylated Raf, nuclear and cytoplasmic expression of MAP Kinase and its’ 
activated, phosphorylated form, with HER2 in ASPC tumours. Significant correlations
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(p<0.05) are highlighted. P values were assessed by Spearman’s Rank Correlation 
Test. Correlation co efficients in brackets. 
pHER2, phosphorylated HER2
pRaf (ser259), inactive phosphorylated Raf ; pRaf (ser338) activated phosphorylated 
Raf
pMAP Kinase, activated phosphorylated MAP Kinase
There were no correlations seen with EGFR in ASPC tumours, however its’ activated, 
phosphorylated form weakly correlated with cytoplasmic pRaf (ser338) (p=0.037). The 
mutant variant, EGFR vIII, did coiTelate strongly with cytoplasmic expression of MAP 
Kinase and pMAP Kinase (p<0.001 and 0.014 respectively) and with Raf-1 to a weaker 
extent (p=0.034). There was weak negative association with nuclear pRaf (ser338) 
(p=0.052) (see Table 8b).
Table 8b. Protein correlations between Raf/MAP Kinase Protein Expression and 
EGFR in ASPC tumours.
EGFR pEGFR EGFRvlll
Raf-1 0.050(0.25) 0.034(0.27)
pRaf (ser259) 0.635(0.60) 0.779(0^04) 0.368(0.12)
pRaf (ser338) (nuclear) 0.973(0.01) 0.688(-0.06) 0.052(-0.27)
pRaf (ser338) (cytoplasm) 0.159(-0.20) 0.037(0.28) 0.628(-0.07)
MAP Kinase (nuclear) 0.96(-0.07) : 0.19(0.18)
MAP Kinase (cytoplasm) 0.45(0.10) <0.001(0.46)
pMAP Kinase (nuclear) 0.054(0.26) 0.59(-0.07) 0.053(0.27)
pMAP Kinase (cytoplasm) 0.14(0.20) 0.47(0.1) 0.014(0.33)
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Table 8b shows correlations (p values) between Raf-1, inactive and active 
phosphorylated Raf, nuclear and cytoplasmic expression of MAP Kinase, and its’ 
activated, phosphorylated form, with EGFR in ASPC tumours. Significant 
correlations (p<0.05) are highlighted. P values were assessed by Spearman’s Rank 
Correlation Test. Correlation co-efficients in brackets. 
pEGFR, phosphorylated EGFR ; EGFR vIII, variant III EGFR
Negative associations were seen between AR and Raf-1 (p=0.016), and between AR and 
nuclear and cytoplasmic expression of pMAP Kinase (p=0.04 and p=0.009 respectively). 
Expression of the androgen-regulated gene, PSA, correlated with nuclear and cytoplasmic 
expression of MAP Kinase (p=0.04 and p=0.016 respectively). This correlation was 
strengthened with activation (pMAP Kinase) (p=0.001 and p<0.001 respectively) (See 
Table 8c).
Table 8c. Correlation Between Raf-l/MAP Kinase Protein Expression with AR and 
PSA in ASPC tumours.
AR PSA
Raf-1 0.016 (-0.30) 0.09 (0.22)
pRaf (ser259) 0.911 (-0.01) 0.298 (0.13)
pRaf (ser338) (nuclear) 0.244 (0.16) 0.385 (0.12)
pRaf (ser338) (cytoplasm) 0.473 (0.10) 0.277 (0.15)
MAP Kinase (nuclear) 0.331 (-0.13) 0.04 (0.38)
MAP Kinase (cytoplasm) 0.124 (-0.20) 0.016 (0.32)
pMAP Kinase (nuclear) 0.043 (-0.27) 0.001 (0.44)
pMAP Kinase (cytoplasm) 0.009 (-0.34) <0.001 (0.45)
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Table 8c shows correlations (p values) between Raf-1, inactive and active 
phosphorylated Raf, nuclear and cytoplasmic expression of MAP Kinase and its’ 
activated, phosphorylated form with AR and PSA in ASPC tumours. Significant 
correlations (p<0.05) are highlighted. P values were assessed by Spearman’s Rank 
Correlation Test. Correlation co efficients in brackets.
AR, androgen receptor
pRaf (ser259), inactive phosphorylated Raf ; pRaf (ser338) active phosphorylated Raf 
pMAP Kinase, activated phosphorylated MAP Kinase
Fiu'ther downstream, activated pRaf (ser338) in the cytoplasm correlated with phosphorylated 
c-jun (p=0.014). There were no correlation seen between MAP Kinase and its’ activated form 
with c-jun nor c-fos (See Table 8d).
Table 8d. Correlation Between Raf-l/MAP Kinase Protein Expression with components 
of AP I in ASPC tumours.
c-jun Phospho c-jun c-fos
Raf-1 0.330(-0.15) 0.411(-0.13) 0.782(0.04)
pRaf (ser259) 0.166(0.21) 0.086(-0.27) 0.364(-0.14)
pRaf (ser338) (nuclear) 0.577(-0.93) 0.134(0.26) 0.528(0.11)
pRaf (ser338) (cytoplasm) 0.577(0.93) 0.014(0.41) 0.437(-0.13)
MAP Kinase (nuclear) 0.13(-0.24) 0.08(-0.28) 0.45(-0.12)
MAP Kinase (cytoplasm) 0.78(0.04) 0.95(-0.01) 0.39(0.14)
pMAP Kinase (nuclear) 0.176(-0.22) 0.101(-0.27) 0.336(0.15)
pMAP Kinase (cytoplasm) 0.192(-0.21) 0.097(-0.27) 0.190(0.21)
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Table 8d shows correlations (p values) between Raf-1, inactive and active 
phosphorylated Raf, nuclear and cytoplasmic expression of MAP Kinase and its’ 
activated, phosphorylated form with the components of AP I. Significant correlations 
(p<0.05) are highlighted. P values were assessed by Spearman’s Rank Correlation Test. 
Correlation co efficients in brackets, 
phospho c-jun, phosphorylated c-jun
pRaf (ser259), inactive phosphorylated Raf ; pRaf (ser338) active phosphorylated Raf 
pMAP Kinase, activated phosphorylated MAP Kinase
3.7.2 Correlation with Other Members of the Pathway -  A Functional Signalling 
Cascade in ASPC?
Type 1 Receptor Tyrosine Kinase Activation in ASPC
Growth factors and their receptors have been consistently linked with the development of 
AIPC. In particular, increased expression of the EGF-receptor family of type 1 receptors 
tyrosine kinases, including the EGFR itself, HER-2 and EGFR vIII (Craft et al., 1999) 
(Shi et a l, 2001) (Olapade-Olaopa et a l, 2000). Membrane bound receptor tyrosine 
kinases activate several known cytoplasmic signal transduction cascades, of which the 
Raf/MAP Kinase is one of the best characterised (Karayi and Markham, 2004). Type 1 
receptor tyrosine kinases have been shown to activate Raf/MAP Kinase pathway in 
prostate cancer cell line experiments (Bell et a l, 2003) (Craft et a l, 1999) (Yeh et a l, 
1999). HER2 and MAP Kinase have both been postulated to act as potential markers of 
disease progression and as therapeutic targets on the basis of in vitro work (Yeh et a l, 
1999). The role of type 1 receptor tyrosine kinases in activating the Raf/MAP Kinase 
pathway was further supported by our findings in vivo.
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In this study, expression of the upstream type 1 tyrosine kinase receptor, HER2, was 
associated with Raf-1 (p-0.019), cytoplasmic MAP Kinase (p=0.02), and nuclear and 
cytoplasmic expression of activated MAP Kinase (p=0.03 and p<0.001 respectively). 
Although these correlations are generally weak (with the exception of HER2 and 
cytoplasmic activated MAP Kinase) the number of associations would indicate that in 
clinical ASPC, HER2 is involved in regulating the MAP Kinase cascade, as previously 
demonstrated in in vitro studies (Yeh et ah, 1999) (Craft et ah, 1999) (Figure 14). A 
weak negative association with HER2 and activated Raf-1 (p=0.06) was also observed, 
whilst HER2 activation correlated positively with inactive Raf-1 (p=0.001). The may 
imply that HER2 in fact inactivates Raf-1, possibly via activation of the PI3K/Akt cascade 
which can result in phosphorylation of Raf-1 at serine 259 (Zimmermann and Moelling, 
1999) (Figure 13). This association may then drive the overall positive correlation 
between HBR2 and total Raf-1. This however would not explain the correlations between 
HER2 and activated MAP Kinase. Furthermore, the negative relationship between HER2 
and activated Raf-1 did not achieve significance. An alternative explanation for the strong 
correlation between HER2 and with pRaf (ser259) may be that HER2 drives the activation 
of MAP Kinase via Raf-1 resulting in its’ rapid inactivation.
A positive correlation was also seen between activated EGFR and activated Raf-1 
(p=0.037). In addition, EGFR vIII correlated with Raf-1 (p=0.034), and cytoplasmic 
expression of MAP Kinase and its’ phosphorylated form (p<0.001 and p=0.014) 
respectively. This may imply that EGFR and its’ variant, in conjunction with HER2, can 
also result in the subsequent downstream activation of the MAP Kinase pathway via Raf-1 
(Figure 14). Furthermore, a positive correlation was seen between pRaf (ser338) and 
phosphorylated c-jun -  a component of the downstream transcription factor AP-1. It is
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tempting to speculate that an activated EGFR/Raf-1/c-jun pathv/ay is present in ASPC as 
correlations between all 3 members are now present.
Interaction with the AR
Interestingly, in vitro studies have speculated a role for HER2 in promoting ARA-AR 
interaction, via MAP Kinase (Yeh et a l, 1999). In support of this, MAP Kinase inliibitors 
have also been demonstrated to inhibit HER2-induced transcriptional activity of AR (Yeh 
et al., 1999). However, in our study, AR expression inversely correlated with Raf-1 
expression (p=0.016) and with the nuclear and cytoplasmic expression of activated MAP 
Kinase (p=0.04 and p=0.009 respectively). As the AR signalling pathway is active in 
ASPC, a possible explanation for this could be that the AR axis is the preferred mode of 
cell growth regulation in ASPC cells, independent of HER2/MAP Kinase (Figure 14).
During androgen deprivation therapy, prostate cancer cells undergo growth arrest and 
apoptosis. Upregulation of the Raf/MAP Kinase pathway may enable AIPC cells to utilise 
the type 1 receptor tyrosine kinase/Raf-l/AP-1 cascade to promote cell growth 
independently of the AR, and compensate for androgen ablation-induced apoptosis. 
Activation of the pathway therefore occurs and eventually drives progression to death. In 
a separate study using the same dataset, rising HER2 expression with the development of 
AIPC was shown to correlate with reduced survival (Bartlett et a l, 2005). This together 
with the survival data on rising MAP Kinase expression from this study would appear to 
support this hypothesis. Furthermore, correlations between all 3 levels of this pathway, 
which begin to appear in ASPC, develop further in AIPC tumours (see next section) 
(Figure 15).
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Figure 14 -  Possible interpretation o f protein correlations seen in patients with  
ASPC
Interestingly, expression o f the androgen-regulated gene, PSA, correlated with nuclear 
and cytoplasmic expression o f  MAP Kinase (p=0.04 and p=0.016 respectively). This 
correlation was strengthened with activated MAP Kinase (p=0.001 and p<0.001 
respectively), which may imply that MAP Kinase activation can drive the transcription o f  
androgen-dependent genes in androgen-sensitive disease, independently o f  the AR (as AR 
correlated inversely with Raf-1 and MAP Kinase). However the ability o f  PSA protein 
expression to act as a marker o f  AR activation and AR-regulated gene expression has 
been questioned as, unlike serum levels, correlations between PSA and AR protein 
expression are often absent. It may be that MAP Kinase expression, like PSA, acts as a 
general marker for prostate cancer, and their association is merely casual rather than 
causal. Interestingly, these correlations were lost in AIPC, however by this stage levels o f  
PSA expression do not reflect the extent o f disease progression and are less useful.
3.7.3 Correlations with Other Proteins in AIPC Tumours
After the development of AIPC, HER2 once again correlated with Raf-1 (p=0.04). Its’ 
weak negative association, seen in ASPC tumours, with cytoplasmic activated pRaf 
(ser338) was now significant (p=0.013) as was a negative correlation with the nuclear 
form (p=0.027). In addition, its’ activated form (pHER2) once again coiTelated weakly 
with Raf-1 and strongly with pRaf (ser259) (p==0.046 and <0.001 respectively) as well as 
with cytoplasmic MAP Kinase expression (p=0.014) (see Table 9a).
Table 9a. Protein correlations between Raf/MAP Kinase and HER2 in AIPC 
tumours.
HER2 pHER2
Raf-1 0.040 (0.31)
pRaf (ser259) 0.456 (0.11) <0.001 (0.60)
pRaf (ser338) (nuclear) 0.027 (-0.35) 0.176 (0.23)
pRaf(ser338) (cytoplasm) 0.013 (-0.38) 0.311 (0.17)
MAP Kinase (nuclear) 0.588 (0.08)
MAP Kinase (cytoplasm) 0.579 (0.09)
pMAP Kinase (nuclear) 0.593 (-0.08) 0.285 (0.18)
pMAP Kinase (cytoplasm) 0.394 (0.13) 0.363 (0.15)
Table 9a shows correlations (p values) between Raf-1, inactive and active 
phosphorylated Raf, nuclear and cytoplasmic expression of MAP Kinase and its’ 
activated, phosphorylated form, with HER2 in AIPC tumours. Significant correlations 
(p<0.05) are highlighted. P values were assessed by Spearman’s Rank Correlation 
Test. Correlation co efficients in brackets. 
pHER2, phosphorylated HER2
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The association between EGFR vIII and Raf-1 (p=0.024) and cytoplasmic MAP Kinase 
(p=0.004) was still present in addition to an association with pRaf (ser259) (p=0.014) 
and nuclear expression of MAP Kinase (p=0.012). Furthermore, the weak negative 
association, seen in ASPC tumours, between with EGFR vIII and cytoplasmic activated 
pRaf (ser338) was now significant (p=0.049) but a much stronger negative correlation 
was seen with the nuclear form (p=0.008) (see Table 9b).
Table 9b. Protein correlations between Raf/MAP Kinase Protein Expression and 
EGFR in AIPC tumours.
Table 9b shows correlations (p values) between Raf-1, inactive and active 
phosphorylated Raf, nuclear and cytoplasmic expression of MAP Kinase and its’ 
activated, phosphorylated form, with EGFR in AIPC tumours. Significant correlations
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EGFR pEGFR EGFRvlll
Raf-1 0.548 (0.07) 0.024(0.28)
pRaf (ser259) 0.560 (-0.07) 0.111(0.20) 0.014(0.30)
pRaf (ser338)
(nuclear)
0.963 (0.01) 0.672 (-0.06) 0,008 (-0.34)
' I
pRaf (ser338)
(cytoplasm)
0.423 (0.11) 0.483 (0.10) 0.049 (-0.26)
MAP Kinase
(nuclear)
0.860 (-0.02) 0.012 (0.32)
MAP Kinase
(cytoplasm)
0.850 (0.02) 0.004 (0.37) I
pMAP Kinase
(nuclear)
0.054 (0.26) 0.590 (-0.07) 0.053 (0.27)
pMAP Kinase
(cytoplasm)
0.250 (0.15) 0.127 (0.20) 0.580 (0.07)
(p<0.05) are highlighted. P values were assessed by Spearman’s Rank Correlation
Test. Correlation co efficients in brackets.
pEGFR, phosphorylated EGFR ; EGFR vIII, variant III EGFR
A weak, positive correlation was seen between cytoplasmic pRaf (ser259) and pMAP 
Kinase with the AR (p=0.04 and 0.023 respectively). There was no correlation (positive 
or negative) now between Raf-1 expression and AR. There were no correlations noted 
with PSA expression (see Table 9c).
Table 9c. Correlation Between Raf-l/MAP Kinase Protein Expression with AR and 
PSA in AIPC tumours.
AR PSA
Raf-1 0.750 (-0.04) 0.960 (-0.07)
pRaf (ser259) 0.023 (0.28) 0.987 (0.00)
pRaf (ser338) (nuclear) 0.720 (-0.05) 0.332 (0.13)
pRaf (ser338) (cytoplasm) 0.748 (-0.04) 0.627 (0.07)
MAP Kinase (nuclear) 0.099 (-0.22) 0.780 (-0.04)
MAP Kinase (cytoplasm) 0.462 (-0.1) 0.806 (0.03)
pMAP Kinase (nuclear) 0.159 (0.18) 0.76 (0.04)
pMAP Kinase (cytoplasm) 0.040 (0.26) 0.95 (0.01)
Table 9c shows correlations (p values) between Raf-1, inactive and active 
phosphorylated Raf, nuclear and cytoplasmic expression of MAP Kinase and its’ 
activated, phosphorylated form with AR and PSA in AIPC tumours. Significant
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correlations (p<0,05) are highlighted. P values were assessed by Spearman’s Rank 
Correlation Test. Correlation co efficients in brackets.
AR, androgen receptor
pRaf (ser259), inactive phosphorylated Raf ; pRaf (ser338) active phosphorylated Raf 
pMAP Kinase, activated phosphorylated MAP Kinase
More correlations were now seen with components of the downstream transcription 
factor AP-1. A strong conelation was still seen between cytoplasmic pRaf (ser338) and 
phosphorylated c-jun (p=0.008), but now there was also one with pRaf (ser259) 
(p=0.005). There was also a correlation seen between Raf-1 and c-fos (p=0.006), and 
between the nuclear expression of pMAP Kinase and c-jun (p=0.025) (see Table 9d).
Table 9d. Correlation Between Raf-l/MAP Kinase Protein Expression with components 
of AP-1 in AIPC tumours.
c-jun Phospho c-jun c-fos
Raf-1 0.460 (0.12) 0.878 (0.02) 0.006 (0.44)
pRaf (ser259) 0.385 (0.14) 0.005 (0.42) 0.286 (0.17)
pRaf (ser338) (nuclear) 0.335 (0.16) 0.123 (0.26) 0.568 (-0.10)
pRaf (ser338) (cytoplasm) 0.330 (0.17) 0.008 (0.43) 0.061 (-0.32)
MAP Kinase (nuclear) 0.706 (0.06) 0.115 (-0.26) 0.532 (0.11)
MAP Kinase (cytoplasm) 0.710 (0.06) 0.820 (0.04) 0.898 (0.02)
pMAP Kinase (nuclear) 0.025 (0.35) 0.245 (0.19) 0.823 (0.04)
pMAP Kinase (cytoplasm) 0.092 (0.27) 0.732 (0.05) 0.780 (0.05)
Table 9d shows correlations (p values) between Raf-1, inactive and active 
phosphorylated Raf, nuclear and cytoplasmic expression of MAP Kinase and its’
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activated, phosphorylated form with the components of AP-1. Significant correlations 
(p<0.05) are highlighted. P values were assessed by Spearman’s Rank Correlation Test. 
Correlation co efficients in brackets, 
phospho c-jun, phosphorylated c-jun
pRaf (ser259), inactive phosphorylated Raf ; pRaf (ser338) active phosphorylated Raf 
pMAP Kinase, activated phosphorylated MAP Kinase
3.7.4 Correlation with Other Members of the Pathway -  A Functional Signalling 
Cascade in AIPC?
Having demonstrated a role for Raf-1 and MAP Kinase expression in the development of 
AIPC, it was important to correlate this expression with other proteins, upstream and 
downstream, involved in the MAP Kinase signal cascade. Immunohistochemical 
determination of these proteins had already been carried out in the laboratory, using the 
same matched cohort of tumours (JE, NSK and KP). By using these results we were able 
to demonstrate that Raf-1 and MAP Kinase protein expression correlated with other 
proteins known to interact with the MAP Kinase signal transduction cascade (Figure 15).
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Figure 15 -  The R af/M A P K inase Pathway — a functioning signalling cascade in 
AIPC developm ent?
Type 1 Receptor Tyrosine Kinase Activation in AIPC
Correlations with the type 1 receptor tyrosine kinases continued with the development o f  
AIPC. However the correlations between HER2 and its’ activated form with Raf-1 were 
weaker (p=0.040 and p=0.046 respectively). Furthermore, activated HER2 correlated 
even more strongly with the inactive form o f Raf-1 (p=<0.001). Its’ weak negative 
association, seen in ASPC tumours, with cytoplasmic activated Raf-1 was now 
significant (p=0.013) as was a negative correlation with the nuclear form o f activated 
Raf-1 (p=0.027). This may imply that HER2 inactivates the Raf-l/MAP Kinase pathway 
-  a relationship that may have been developing in ASPC. In support o f this, the 
association between HER2 and MAP Kinase was also weakened with the development o f  
AIPC, with only a single correlation with cytoplasmic MAP Kinase expression present 
(p=0.014).
In the case of EGFR vIII, the pattern of correlations with Raf-1 was similar to HER2. 
The association between EGFR vIII and Raf-1 (p=0.024) was still present perhaps driven 
by a strong association with inactive Raf-1 (p=0.014). In support of this, the weak 
negative association seen in ASPC tumours, between with EGFR vIII and cytoplasmic, 
activated Raf-1 (ser338), was now significant (p=0.049) along with a much stronger 
negative correlation with the nuclear form (p=0.008). Taken together this data implies 
that EGFR vIII also inactivates Raf-1. Despite this, strong positive correlations between 
EGFR vIII were still present with the nuclear and cytoplasmic expression of MAP 
Kinase (p=0.012 and p=0.004 respectively), although the relationship with its’ activated 
form was now lost. No correlations were seen between EGFR and its’ activated form 
with Raf-1 or MAP Kinase.
Whilst there is evidence linking type 1 receptor tyrosine kinases with AIPC via the MAP 
Kinase pathway in cell-line studies (Yeh et ah, 1999) (Craft et al., 1999), this study may 
suggest that this axis, whilst present in ASPC, is lost in AIPC in vivo. HER2 and EGFR 
may be acting via other signal pathways, such as PI3K/Akt which inhibits Raf-1 by direct 
phosphorylation of serine 259 as mentioned earlier (Figure 13) (Zimmermann and 
Moelling, 1999). Both HER2 and EGFR are both known to activate the PI3K/Akt 
pathway, promoting androgen-independent tumourigenesis via the AR in the absence of 
androgen (Zhou et al., 2000) (Wen et al., 2000). In support of this, it has been shown that 
inhibition of MAP Kinase does not completely block HER2 activation of the AR, further 
implicating the role of other signal cascades in the promotion of androgen-insensitive 
growth. Furthermore, MAP Kinase expression has been noted to decrease with prostate 
cancer progression in a study using a transgenic mouse model, whilst remaining high in 
the early stages of cancer and correlating with cell proliferation (Uzgare et al., 2003).
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& Whilst this study speculated a role for MAP Kinase in initiating prostate carcinogenesis, 
inactivation was thought to be associated with the development of androgen- 
independence. It is important, however, to use caution when comparing these results with 
those using clinical prostate cancer specimens as any differences noted may be a 
reflection of the difficulties in creating accurate model systems for studying prostate 
cancer.
The survival data yielded from this study however would indicate that the Raf/MAP 
Kinase pathway still plays a crucial role in the development of AIPC. It may be the case 
that in AIPC alternative receptor tyrosine kinases can activate Raf-1. One may speculate a 
greater role for other members of the type 1 receptor tyrosine kinase family, such as HER3 
or HER4 in the activation of the Raf/MAP Kinase cascade in AIPC. Other growth factor 
pathways may also be involved, for example the IL-6R cascade, which is known to 
interact and stimulate the MAP Kinase cascade directly (Ueda et al., 2002b). Interestingly, 
HER2 is also thought to be a central component of IL-6 signalling via MAP Kinase in 
prostate cancer with co-activation of HER3 (Qiu et al., 1998). It appears that the control 
and activation of the cascade, in general, becomes increasingly dysregulated with the 
development of androgen-insensitive disease, as one would expect. The AIPC samples in 
this study were retrieved once biochemical relapse was well established, and it may be that 
earlier sampling, (perhaps closer to the moment of actual moment of AIPC development) 
would still have detected ongoing strong correlations with HER2/EGFR and the Raf/MAP 
Kinase pathway.
However, as discussed earlier in ASPC tumours, an alternative explanation for the 
negative and positive correlations seen with active and inactive Raf-1 respectively may yet
137
be that HER2 or EGFR vIII drives the activation of MAP Kinase via Raf-1 resulting in its’ 
rapid inactivation, Raf-1 activation status is also regulated by cross-talk with other signal 
transduction cascades, for example its’ negative regulation by the PI3K/Akt pathway 
(Zimmermami and Moelling, 1999) (Figure 16). Alternatively, Raf-1 may be activated by 
PKC (Edwards et al., 2004). As mentioned earlier, these pathways may also be co­
activated by growth factor receptors including the type 1 receptor tyrosine kinases with the 
development of AIPC (Wen et al., 2000) (Lee et al., 2002). PKA is also known to directly 
phosphorylate serine 259 and activate MAP Kinase (Dhillon et ah, 2002b) (Ueda et al., 
2002b) (Lee et al., 2002). In doing so, androgen-independent growth may be furthered, 
whilst Raf-1 is re-cycled to the membrane for further activation.
Interaction with the AR
Interestingly, the negative correlations previously noted between the Raf/MAP Kinase 
and the AR were no longer present. Instead, weak positive correlations were now seen 
between cytoplasmic pMAP Kinase and pRaf (ser259) with the AR (p=0.04 and 0.023 
respectively). MAP Kinase activation of the AR by phosphorylation via phosphorylation 
at serine 515 in vitro is well documented. MAP Kinase can increase transcription of 
androgen-dependent genes, independently of androgens, via AR phosphorylation (Abreu- 
Martin et ah, 1999) (Bakin et al., 2003) (Ueda et al., 2002b) (Franco et al., 2003) 
(Rochette-Egly, 2003). The AR therefore may now be acting as a target for MAP Kinase 
in AIPC (Figure 16). However, there is currently no evidence to demonstrate that this 
occurs in AIPC in vivo or even if phosphorylation by MAP Kinase has any clinical 
relevance. Correlations between activated MAP Kinase and phosphorylated AR (serine 
515) would support a role for MAP Kinase phosphorylation of the AR however there is 
no commercially available antibody, as yet, to determine this.
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Raf/MAP Kinase Interaction with AP-1
The MAP Kinase cascade has also been demonstrated in vitro to stimulate prostate caneer 
cell growth independently of the AR (Magi-Galluzzi et al., 1997). This study 
demonstrated activation of the transcription factor AP-1 as an alternative target for the 
Raf/MAP Kinase pathway, resulting in cell growth and survival. Raf-1 and MAP Kinase 
now correlated with c-fos and c-jun, components of the downstream transcription factor 
AP-1 - a known target of the pathway (Abreu-Martin et al., 1999) (Weinstein- 
Oppenheimer et al., 2000). Strong con’elations were seen between Raf-1 and c-fos 
(p=0.006), activated and inactivated Raf-1 and phosphorylated c-jun (p=0.0Q8 and 0.005 
respectively), and the nuclear expression of pMAP Kinase with c-jun (p=0.025). Hence, 
activation of the Raf-l/MAP Kinase pathway may influence AP-1 formation, leading to 
increased levels of its’ components, in clinical AIPC patient specimens. In vitro studies 
have already demonstrated that Raf-1 regulates c-fos expression and, once activated, Raf- 
1 can phosphorylate and hence activate c-jun, via MAP kinase (Weinstein-Oppenheimer 
et al., 2000). Once again, the rapid inactivation of Raf-1 once AP-1 has formed may 
explain why pRaf (ser259) correlated with phosphorylated c-jun.
Activated MAP Kinase may therefore stimulate prostate cancer cell growth independently 
of the AR via activation of AP-1 (Figure 16) (Weinstein-Oppenheimer et al., 2000). The 
AP-1 transcription factor is involved in the control of cell growth and differentiation as 
well as apoptosis, and is thought to he the convergence point of several signalling 
pathways leading to carcinogenesis (Church et al., 2005). As such, it has already been 
linked with AIPC progression (Sato et al., 1997) (Bubulya et al., 2001) (Church et al.,
2005). Its’ formation and activation requires phosphorylated c-jun forming homodimers 
or heterodimers with c-fos. Phosphorylation of c-jun may be stimulated by MAP Kinase
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in cell-line studies (Sato et al., 1997) (Wyke et al., 1996). The concentration o f c-jun and 
c-fos has been noted to be several times greater in androgen-insensitive compared to 
sensitive cell-lines (Sato et al., 1997). Furthermore, the MAP Kinase pathway is known to 
stimulate AP-1 transcriptional activity in AR-positive and negative cells (Abreu-Martin et 
al., 1999). MAP Kinase may also effect transcription o f c-fos resulting in its’ upregulation 
(Wyke et al., 1996). Upregulation o f RKIP (Raf-1 inhibitory protein), which is known to 
disrupt Raf-1 and MEK interaction, causes inhibition o f  the cascade and subsequent AP-1 
dependent transcription (Yeung et al., 2000).
EGFR HER2
?other pathways
Increase proliferation
Figure 16 -  Possible interpretation o f  protein correlations seen in patients with AIPC
AP-1 and its’ components are known to cross-talk with the AR (Church et al., 2005). AP- 
1 can inhibit AR gene transcription by direct binding with the receptor (Sato et al., 1997) 
(Edwards et al., 2004). In turn, AP-1, acting as an independent transcription factor, may 
activate androgen-regulated genes, stimulating prostate cancer cell growth independently
of the AR (Sato et ah, 1997). The PSA promoter site, for example, contains a specific 
binding site for AP-1 possibly allowing for AR-iiidependent transcription via the MAP 
Kinase pathway. It has been postulated that a relative increase in the cellular AP-l/AR 
ratio would result in a “switch” to AP-1 regulation of (androgen-dependent) gene 
expression (Edwards et ah, 2004). Interestingly, activation of the AR in a recent study 
using the LNCaP cell-line, can also result in growth arrest, with co-stimulation of AP-1 
mediated gene transcription (Church et ah, 2005). The composition of AP-1 in this study 
was also altered, as a result, in favour of c-jun. In addition, c-jun, in its’ 
unpliosphorylated form, acts as an AR co-activator, promoting AR homodimerisation 
and increasing its’ transactivation ability in the absence of ligand (1516} (Bubulya et ah, 
2001). In support of this, overexpression of c-jun in androgen-insensitive cell lines, can 
increase AR activation (Tillman et ah, 1998). C-jun can also prevent the inhibitory 
effects of the AR co-repressor, p53 (Lee and Chang, 2003). Upregulation of c-jun may 
therefore be another mechanism by which MAP kinase can activate the AR to effect 
androgen-independent growth (Zhu and Liu, 1997).
The role of AP-1 and its’ components is therefore complex. Work in our own laboratory 
has already linked increased phosphorylated c-jim expression with androgen-resistance 
(Edwards et ah, 2004). Using the same database of paired patient samples, this study 
demonstrated high phosphorylated c-jun expression in over 60% of patients with AIPC. 
Interestingly, this resulted in a reduction in time to death from relapse (from 5.5 years to 
1.87 years) in patients with high expression of phosphorylated c-jun (Edwards et ah, 
2004). Concomitant progressio n of disease should translate into potential cancer specific 
survival which may explain the association between rising MAP Kinase expression and 
reduced overall survival.
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The mechanism of AIPC development in this patient cohort may well be increased AP-1 
expression, driven by the phosphorylation of c-jun by MAP Kinase. This in turn would 
lead to AR suppression and AP-1 mediated “bypass”, as speculated earlier. In support of 
this, data in the current study revealed positive correlations between Raf-1, c-fos and 
phosphoiylated c-jun with the development of AIPC and ASPC. However the correlation 
between MAP Kinase with unphosphorylated c-jun may indicate that the pathway can 
also act via c-jun alone, albeit to a lesser extent.
However it may be argued that such protein correlations may be casual rather than 
causal. Rising Raf-1 and MAP Kinase expression in prostate cancer may be a result of, 
rather than the effect of, tumour progression. However the sheer extent and number of 
protein correlations with kno’wn activators and targets of the pathway, and, more 
importantly, the impact of Raf-1 and MAP Kinase on relapse and survival would imply a 
more direct role for the pathway in the development of AIPC. To further test the clinical 
relevance of the Raf/MAP Kinase pathway in vitro, assays simulating the physiological 
state of androgen-deprivation with activation by growth factors are required (Yeh et al.,
1999).
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3.8 Tissue Micro Arrays
3.8.1 Correlations with Tissue Micro Arrays
Interclass correlation coefficients were then calculated to assess the accuracy of each 
core in predicting histoscore from the full section (see Table 10). In total 55 sections had 
tissue suitable for obtaining cores. As correlations were generally poor (ICCC<0.50), 
TMAs were not stained for pRaf (ser338) nor pMAP Kinase.
Table 10
Raf-1 pRaf
(ser259)
MAP
Kinase
(nuclear)
MAP
Kinase
(cytoplasm)
ICCC 0.24 0.50 0.17 0.06
(Full section vs
correspondingTMA)
Table 10 shows interclass correlation coefficients between median histoscores for TMA 
cores compared with median histoscores for the corresponding full section.
ICCC, inter-class correlation co-efficient
pRaf (ser259), inactive phosphorylated Raf
pMAP Kinase, activated phosphorylated MAP Kinase
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3.8.2 Use of TMAs in prostate cancer
High density TMAs are widely used for the rapid screening of multiple tumour sections 
for protein expression, allowing large-scale retrospective studies of archival tissue (Camp 
et ah, 2000) (Kononen et ah, 1998) (Kirkegaard et ah, 2005). By constructing a single 
tissue block containing cores from several patients, TMAs have the advantage of 
conserving tissue and standardising experimental conditions (Perrone et ah, 2000). The 
sampling and coring of small specific tumour areas should reduce tissue staining 
heterogeneity due to non-cancerous tissue which can be observed from analysis of full 
tissue sections (Kirkegaard et ah, 2005). Despite the small size of cores, inter-observer 
variability has been shown to be just as low in TMAs, compared with full sections 
(Kirkegaard et ah, 2005).
TMAs have already been used for high throughput analysis of prostate cancer specimens 
(Perrone et ah, 2000). In order to analyse the effectiveness of TMAs in prostate cancer in 
this study, cores were taken from tissue blocks (if suitable) and transferred into an array 
block. Fifty five sections were cored in total. In breast TMAs, 0.6 mm cores are routinely 
used, however prostate cancer is a more heterogeneous cancer both in terms of tumour 
histology and differentiation. As a result the grades from the most prevelant regions are 
combined to form the Gleason score. Larger areas of tissue (containing as much of the 
cancerous regions as possible) are therefore required to provide a true representation as 
different tumour regions may have varying levels of protein expression (Camp et ah,
2000) (Perrone et ah, 2000). We therefore increased the core size to 1 mm and included 2 
cores from high and loss Gleason areas to combat this.
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However, we still observed poor correlations between TMA cores and full sections. This 
is in direct contrast with previous results in breast cancer, where use of 2 cores alone 
were representative of the entire tumour (Camp et al., 2000). It may be possible to 
compensate for this by extracting multiple cores (up to 6) from tissue blocks to truly 
reflect the tumour specimen, as has has been carried out previously in tissue derived from 
radical prostatectomies (Perrone et al., 2000) (Fergenbaum et al., 2004). However this is 
often not technically feasible using tissue blocks containing TURP chippings (and 
certainly not for TRUS biopsies) which are not large enough in terms of depth and 
surface area for multiple coring to take place. As such, this study supports the use of full 
tissue sections only when conducting immunohistochemical analyses of protein 
expression in samples of prostate cancer only.
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GENERAL DISCUSSION AND
CONCLUSIONS
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4.1 Introduction
Androgen-insensitive prostate cancer is forecast to be an increasing problem in the 
immediate future (Beemsterboer et ah, 1999). Whilst the AR signalling pathway plays a 
central role in prostate carcinogenesis as well as its’ treatment, it is now understood that 
the progression to AIPC may involve several possible changes, which may not be 
confined to the AR itself. The unravelling of the various molecular profiles or pathways 
which result in AIPC is crucial therefore for the development of novel therapeutic 
strategies.
Previous research in om* laboratory has implicated the MAP Kinase pathway in the 
development of AIPC using comparative gene array analysis (Edwards et ah, 2003b). 
Based on the genetic changes found in this study, we hypothesised that the MAP Kinase 
pathway plays a crucial role in promoting the development of androgen-insensitive 
disease. To test this hypothesis we assessed the protein expression and activation status of 
Raf-1 and MAP Kinase, critical members of the pathway, using immunohistochemistry 
and determined if this had any impact on clinical parameters. We then correlated their 
expression with the expression of known activators of the MAP Kinase cascade (the type 
1 receptor tyrosine kinases EGFR and HER2), a known downstream target (AP-1), as well 
as expression of the androgen receptor itself. This would provide evidence to suggest a 
ftmctional pathway was in fact present with the development of AIPC. In order to cany 
out the study, a unique database consisting of matched, paired ASPC and AIPC specimens 
from the same patients was developed.
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4.2 Raf/MAP Kinase Pathway As A Novel Therapeutic Target
The Raf/MAP Kinase pathway is thought to play an important role in promoting cell 
proliferation and preventing apoptosis. If modest statistical benefits in terms of survival 
can be shown, then these may well represent significant clinical benefits in individual, 
often elderly patients (Klotz, 2001). Therefore it could be argued that the molecular 
selection of patients may be valuable in identifying groups of individuals or subset of 
patients who would benefit from Raf/MAP Kinase pathway inliibition. The ability of the 
MAP Kinase pathway to inhibit apoptosis depends on its’ environmental context, for 
example in response to chemotherapeutic or radiation-induced stress (Abreu-Martin et ah, 
1999) (Hagan et al., 2000). This may render targeting of its’ activation status a useful 
therapeutic strategy. Interestingly, activation of Raf-1 and MAP Kinase has been shown to 
be inhibited by the 5-alpha-reductase inhibitor, finasteride (Huynla, 2002), which may 
result its’ anti-proliferative and pro-apoptotic effects. Specific inhibitors to Ras and Raf 
function have been developed e.g farnesyl tranferase (FT) inhibitors and anti-sense 
oligodeoxyribonucleotides. Many of these compounds are showing promising results in 
clinical trials (Weinstein-Oppenlieimer et a l, 2000). Interference with the pathway by 
specific drugs in such a manner may represent a novel means of improving anti-cancer 
therapy, perhaps as an adjunct to current chemotherapeutic approaches (Figure 1) (Karayi 
and Markham, 2004).
Recent studies have yielded promising results in the form of combination therapy, 
between standard chemotherapeutic agents or radiotherapy and novel drugs aimed at 
molecular targets. Radiotherapy is known to activate various signalling pathways and 
irradiation of DU-145 cells has been shown to cause EGFR-dependent activation of the 
MAP Kinase pathway, resulting in cell proliferation and survival (Hagan et a l, 2000).
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Inhibition of the MAP Kinase pathway by the known pharmacological inhibitors U0126 
and PD98059 (which target different sites on MEK) however results in increased 
radiation-induced G2/M phase growth an*est and apoptosis. As such, EGFR/MAP Kinase 
inhibition may be used to increase radiation-indueed eell kill as an adjunct to radical or 
palliative radiotherapy. Another recent study demonstrated a 20% increase in docetaxel- 
induced growth suppression of androgen-independent LNCaP cells when MAP Kinase 
inhibition (by PD98059) was included (Zelivianski et al., 2003). In addition, enhanced 
apoptosis secondary to further bcl-2 inactivation and bax upregulation was also seen. Its’ 
combination with docetaxel may result in reduced clinical cytotoxicity as a result of 
reduced dosage. Together, this implies a further role for MAP Kinase inliibition in AIPC 
multidrug chemotherapy, especially in cases where activation of the pathway occurs 
(Figure 1) (Zelivianski et a l, 2003).
New specific strategies aimed at reversing the molecular changes that underlie prostate 
tumourigenesis are being developed. It is perhaps not surprising however that no single 
oncogene product has been linked exclusively or conclusively with the progression of 
prostate cancer to androgen-insensitive disease (Karayi and Markham, 2004) and instead a 
variety of biological markers and signal transduction pathways have been linked with 
AIPC. It is becoming increasingly apparent that several of these, when altered or 
overexpressed, will play a role in the disease at least in a proportion of patients. As 
multiple mechanisms or pathways are responsible for escaping androgen control, a 
multimodal management of AIPC is likely in the future (Feldman BJ and Feldman D,
2001) (Culine and Droz, 2000).
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Figure 1. Raf/MAP Kinase Pathway with therapeutic sites of action.
mAh -  monoclonal antibodies e.g. herceptin
FT inhibitors -  farnesyl tranferase (FT) inhibitors (aimed at Ras)
Anti-sense Raf therapy - anti-sense oligodeoxyribonucleotides (aimed at Raf) 
U0126 / PD98059 -  specific MEK inhibitors
4.3 CONCLUSIONS
In summary, the data compiled in this thesis provides the first clinical evidence to support 
the hypothesis that the Raf/MAP Kinase pathway is utilised in AIPC. This pathway plays a 
role in promoting its’ development and progression as their expression significantly impacts 
on time to biochemical relapse and overall survival. In addition, correlations with type 1 
tyrosine kinase receptors and components of AP-1 (c-fos and c-jun) in AIPC tumours, may 
indicate a funetional pathway in the development of AIPC.
Further analysis of this pathway, and its’ role in AIPC using clinical material, are clearly 
warranted. These findings lead us to hypothesise that expression of Raf-1 and MAP 
Kinase would yield useful predictive information for patients at risk of AIPC. Targeting 
of the type 1-tyrosine kinase receptor/Raf-MAP Kinase /AP-1 axis in selected patients 
may yield a novel and exciting therapeutic avenue, consistent with early trials that are 
already underway.
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APPENDIX 2
Scatter graph and Bland-Altman plots demonstrating inter-observer variation for 
each protein.
Figure la  -  Scatter-graph plot demonstrating inter-observer variation for Raf-1
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Figure lb -  Bland-Altman plot demonstrating inter-observer variation for Raf-1
âC  200 328wS 100 
§
I ”Jd0
1g -100
(Ua
8§ -200 I
♦ 1«0
Observer 1 histoscore
177
Figure 2a -  Scatter-graph plot dem onstrating inter-observer variation for pR af (ser259)
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Figure 2b -  Bland-Altman plot demonstrating inter-observer variation for pRaf (ser259)
300
â§ 200IIW 100z
S2
Ë
I  °0
1£  -100
1«0 250150K** 200
ô) -200
S
-300
Observer 1 histoscore
178
Figure 3a -  Scatter-graph plot dem onstrating inter-observer variation for
nuclear pR af (ser338)
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Figure 3b -  Bland-Altman plot demonstrating inter-observer variation for 
nuclear pRaf (ser338)
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Figure 3c -  Scatter-graph plot dem onstrating inter-observer variation for
cytoplasm ic pR af (ser338)
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Figure 3d -  Bland-Altman plot demonstrating inter-observer variation for 
cytoplasmic pRaf (ser338)
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Figure 4a -  Scatter-graph plot dem onstrating inter-observer variation for
cytoplasm ic M AP K inase expression
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Figure 4b -  Bland-Altman plot demonstrating inter-observer variation for 
cytoplasmic MAP Kinase expression
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Figure 5a -  Scatter-graph plot dem onstrating inter-observer variation for nuclear
M AP K inase expression
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Figure 5b -  Bland-Altman plot demonstrating inter-observer variation for nuclear 
MAP Kinase expression
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Figure 6a -  Scatter-graph plot dem onstrating inter-observer variation for
cytoplasm ic pM AP K inase expression
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Figure 6b -  Bland-Altman plot demonstrating inter-observer variation for 
cytoplasmic pMAP Kinase expression
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Figure 7a -  Scatter-graph plot dem onstrating inter-observer variation for nuclear
pM AP K inase expression
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Figure 7b -  Bland-Altman plot demonstrating inter-observer variation for nuclear 
pMAP Kinase expression
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APPENDIX 3
Box-plots and Line Graphs highlighting changes in protein histoscore for each 
protein.
Figure 9.
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Median Raf-1 histoscores for ASPC and AIPC tumours, with p value as assessed 
by Wilcoxon Signed Ranks Test.
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Figure 10. Changes in Raf-1 expression w ith the developm ent o f AIPC
Patients whose Raf-1 expression rose with the development of AIPC300
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Figure 13a. M edian pR a f (ser259) histoscores for ASPC and AIPC tum eurs, with p
value as assessed by W ilcoxon Signed Ranks Test.
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Figure 13b. M edian pR a f (ser338) nuclear and cytoplasm ic histoscores for ASPC
and AIPC tum ours, with p value as assessed by W ilcoxon Signed Ranks Test.
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Figure 14a.
Changes in nuclear pR af (ser259) expression w ith the developm ent o f AIPC
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Figure 14b.
Changes in nuclear pR af (ser338) expression w ith the developm ent o f  AIPC
Patients whose nuclear pRaf (ser338) expression rose with the 
development of AIPC
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Figure 14c.
Changes in cytoplasm ic pR af (ser338) expression w ith the developm ent o f AIPC
Patients whose cytoplasmic pRaf (ser338) expression rose with
development of AIPC250
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Patients whose cytoplasmic pRaf (ser338) expression fell or 
remained unchanged with the developmwnt of AIPC
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Figure 15.
M edian M AP K inase nuclear and cytoplasm ic histoscores for ASPC and AIPC
tumours, with p value as assessed by W ilcoxon S igned Ranks Test
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Figure 16.
M edian pM AP K inase nuclear and cytoplasm ic histoscores for ASPC and AIPC
tumours, with p value as assessed by W ilcoxon S igned Ranks Test
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Figure 17a.
Changes in nuclear M AP K inase expression w ith the developm ent o f AIPC
Patients whose nuclear MAP Kinase expression rose with the 
development of AIPC
Patients whose Nuclear MAP Kinase expression fell or remained 
unchanged with the development of AIPC.
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Figure 17b.
Changes in cytoplasm ic M AP K inase expression w ith the developm ent o f AIPC.
Patients whose cytoplasmic MAP Kinase expression rose with the
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Figure 18a.
Changes in nuclear pM AP K inase expression w ith the developm ent o f  AIPC.
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Figure 18b.
Changes in cytoplasm ic pM AP Kinase expression w ith the developm ent of AIPC.
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APPENDIX 4
Tables highlighting Time to Relapse, Time to Death from relapse, and Overall 
Survival for each protein.
Table la. Time to Relapse (TTR) and Raf-1 / pRaf expression divided by median.
TTR (years) P value
Raf-1 Below Median 1.90 (1 .45-2 .35)
Above Median 3.40 (2.27-4.53) 0.07
pRaf (ser259) Below Median 2.28 (1.88-2.69)
Above Median 2.58 (1.31-3.83) 0.79
pRaf (ser338) Nuclear Below Median 2.35(1.92-2.77)
Above Median 2.98(1.46-4.50) 0.93
pRaf (ser338) Cytoplasm Below Median 2.36 (2.08-2.64)
Above Median 2.98 (0.64-5.32) 0.16
Raf-1 and pRaf expression, split into 2 subgroups - above and below median - is shown 
related to median time to relapse in days (with inter-quartile ranges in brackets). Significance 
is shown by p values, assessed by Kaplan-Meier analysis.
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Table lb . Tim e to R elapse (TTR) and Raf-1 /  pR af expression d ivided according to
rising liistoscore w ith developm ent o f AIPC.
TTR years) P value
Raf-1 Non-Risers 2.62 1.52 -3 .70)
Risers 1.16 1 .12 -1 .20) 0.0005
pRaf (ser259) Non-Risers 2.36 1.98-2.73)
Risers 2.57 0-5.41) 0.68
pRaf (ser338) Nuclear Non-Risers 2.30 1.72-2.88)
Risers 2.30 1.75-2.85) 0.75
pRaf (ser338) Cytoplasm Non-Risers 2.30 1.86-2.74)
Risers 2.60 2.14-3.06) 0.79
pRaf (ser338) Nuclear Failers 4.60 3.40-5.80)
Non-Fallers 2.20 1.84-2.56) 0.01
pRaf (ser338) Cytoplasm Failers 2.40 0-4.95)
Non-fallers 2.30 1.93-2.67) 0.56
Raf-1 and pRaf expression, split into 2 subgroups - risers and non-risers with the 
development of AIPC - is shown related to median time to relapse in years (with inter­
quartile ranges in brackets). Significance is shown by p values, assessed by Kaplan-Meier 
analysis.
„ ::
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Table 2a. Tim e to Death from Relapse (TTDR) and R af-1/ pR af
expression d ivided according to m edian.
TTDR (years) P value
Raf-1 Below Median 1.6 (1 .4 7 - 1.73)
AIPC
Above Median 2.1 (0.43-3.77) 0.25
pRaf (ser259) Below Median 2.47 (0.76-4.18)
AIPC
Above Median 1.40 (1.20-1.60) 0.11
pRaf (ser338) nuclear Below Median 1.34 (1.16-1.52)
AIPC
Above Median 2.47 (1.14-3.79) 0.15
pRaf (ser338) cytoplasm Below Median 1.37 (1.15-1.59)
AIPC
Above Median 2.15(1.10-3.20) 0.36
Raf-1 and pRaf expression (ASPC and AIPC), split into 2 subgroups - above and below 
median - is shown related to median time to death from relapse in years (with inter-quartile 
ranges in brackets). Significance is shown by p values, assessed by Kaplan-Meier analysis.
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Table 2b. Tim e to Death from  Relapse (TTDR) and Raf-1 / pR af expression divided
according to rising h istoscore w ith developm ent o f AIPÇ.
TTDR (years) P value
Raf-1 AIPC Non-Risers 1.62 (1 .19-2 .05)
Risers 7.30 (-) 0.13
pRaf (ser259) AIPC Non-Risers 1.87 (1 .23-2 .41)
Risers 0.83 ( 0 -  1.66) 0.08
pRaf (ser338) nuclear 
AIPC
Non-Risers 1.62 (1.15-2.10)
Risers 2.47 (0.93-4.00) 0.94
pRaf (ser338) cytoplasm  
AIPC
Non-Risers 1.65 (1.23-2.07)
Risers 1.49 (0.65-2.33) 0.30
Raf-1 and pRaf expression, split into 2 subgroups - risers and non-risers with the 
development of AIPC - is shown related to median time to relapse in years (with inter­
quartile ranges in brackets). Significance is shown by p values, assessed by Kaplan-Meier 
analysis.
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Table 3a. Overall Survival (OS) and Raf-1/ pRaf expression divided according to 
median.
OS (years) P value
Raf-1 Below Median 4.39 (1.58-7.2)
ASPC
Above Median 6.50 (5.83-7.17) 0.60
Raf-1 Below Median 6.04 (2.77-9.31)
AIPC
Above Median 6.26 (4.40-8.12) 0.55
pRaf (ser259) Below Median 6.26 (3.51-9.01)
ASPC
Above Median 6.07 (3.86-8.28) 0.68
pRaf (ser259) Below Median 6.07 (5.03-7.11)
AIPC
Above Median 4.39 (0.77-8.01) 0.32
pRaf (ser338) nuclear Below Median 6.26 (3.61-8.91)
ASPC
Above Median 6.65 (5.37-7.93) 0.29
pRaf (ser338) cytoplasm Below Median 6.57 (4.02-9.12)
ASPC
Above Median 6.04 (5.23-6.85) 0.23
pRaf (ser338) nuclear Below Median 5.51 (3.24-7.78)
AIPC
Above Median 6.65 (5.54-7.76) 0.84
pRaf (ser338) cytoplasm Below Median 6.07 (3.48-8.65)
AIPC
Above Median 6.65 (3.51-9.79) 0.55
Raf-1 and pRaf expression (ASPC and AIPC), split into 2 subgroups - above and below 
median - is shown related to median overall survival in years (with inter-quartile ranges in 
brackets). Significance is shown by p values, assessed by Kaplan-Meier analysis.
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Table 3b. O verall Survival (OS) and Raf-1 /  pR af expression d ivided according to
rising h istoscore with developm ent o f AIPC.
OS (years) P value
Raf-1 Non-Risers 6.07 (4 .85-7 .29)
Risers 8.48 (-) 0.88
pRaf (ser259) Non-Risers 6.07 (4.91-7.23)
Risers 4 .36(1 .88 -6 .84) 0.88
pRaf (ser338) nuclear Non-Risers 5.51 (3.07-7.95)
Risers 7.55 (3.49-11.61) 0.84
pRaf (ser338) cytoplasm Non-Risers 6.65 (3.28-10.02)
Risers 6.04 (3.78-8.30) 0.31
Raf-1 and pRaf expression, split into 2 subgroups - risers and non-risers with the 
development of AIPC - is shown related to median overall survival in years (with inter­
quartile ranges in brackets). Significance is shown by p values, assessed by Kaplan-Meier 
analysis.
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Table 4a. Time to Relapse (TTR) and MAP Kinase / pMAP Kinase expression 
divided by median.
TTR (years) P value
MAP Kinase (Nuclear) Below Median 
Above Median
2.47 (0.62-4.32) 
2.36(1.90-2.82) 0.65
MAP Kinase (Cyto) Below Median 
Above Median
2.36(1.73-2.99)
2.57(1.71-3.43) 0.82
pMAP Kinase (Nuclear) Below Median 
Above Median
2.13(1.39-2.87) 
2.62 (1.09-4.16) 0.06
pMAP Kinase (Cyto) Below Median 
Above Median
2.29 (1.87-2.72) 
2.98(1.49-4.46) 0.08
Nuclear and cytoplasmic MAP Kinase and pMAP Kinase expression, split into 2 subgroups - 
above and below median - is shown related to median time to relapse in days (with inter­
quartile ranges in brackets). Significance is shown by p values, assessed by Kaplan-Meier 
analysis.
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Table 4b. Tim e to Relapse and M AP K inase / pM AP K inase expression divided
according to rising h istoscore with developm ent o f AIPC.
TTR (years) P value
MAP Kinase (Nuclear) Non-Risers
Risers
3.26 (1.94-4.58) 
1.77(1.39-2.15) 0.10
MAP Kinase (Cyto) Non-Risers
Risers
2.35(1.42-3.28) 
2.36 (1.71-3.01) 0.94
pMAP Kinase (Nuclear) Non-Risers
Risers
2.57 (1.39-3.76) 
2.47 (1.20-3.75) 0.25
pMAP Kinase (Cyto) Non-Risers
Risers
2.62 (1.60-3.65) 
2.25 (1.42-3.07) 0.06
Nuclear and cytoplasmic MAP Kinase expression, divided into 2 subgroups -  risers and non­
risers with the development of AIPC - is shown related to median time to relapse in days 
(with inter-quartile ranges in brackets). Significance is shown by p values, assessed by 
Kaplan-Meier analysis.
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Table 5a. Tim e to Death from R elapse (TTDR) and M AP K inase / pM AP
K inase expression d ivided according to m edian.
TTDR (days) P value
MAP Kinase (Nuclear) 
AIPC
Below Median 
Above Median
1.87(1.11-2.63) 
1.60 (0.83-2.37) 0.73
MAP Kinase (Cyto) 
AIPC
Below Median 
Above Median
2.47 (0.03-4.90) 
1.65(1.12-2.18) 0.40
pMAP Kinase (Nuclear) 
AIPC
Below Median 
Above Median
1.65 (0.81-2.48) 
1.87 (1.03-2.71) 0.42
pMAP Kinase (Cyto) 
AIPC
Below Median 
Above Median
2.15(1.44-2.86)
1.60(1.25-1.96) 0.86
Nuclear and cytoplasmic MAP Kinase expression (ASPC and AIPC), split into 2 subgroups - 
above and below median - is shown related to median time to death from relapse in days 
(with inter-quartile ranges in brackets). Significance is shown by p values, assessed by 
Kaplan-Meier analysis.
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Table 5b. Tim e to death from  relapse (TTDR) and M AP K inase / pM AP Kinase
expression d ivided according to rising h istoscore w ith developm ent of
AIPC.
TTDR (years) P value
MAP Kinase (Nuclear) Non-Risers 3.00 (1.43-4.57)
Risers 1.40 (1.20-1.61) 0.0255
MAP Kinase (Cyto) Non-Risers 2.15(1.14-3.16)
Risers 1.58 (0.70-2.46) 0.61
pMAP Kinase (Nuclear) Non-Risers 1.62 (1.17-2.08)
Risers 3.08(1.92-4.24) 0.58
pMAP Kinase (Cyto) Non-Risers 1.65(1.09-2.21)
Risers 2.47 (1.05-3.88) 0.36
Nuclear and cytoplasmic MAP Kinase expression (ASPC and AIPC), divided into 2 
subgroups -  risers and non-risers with the development of AIPC - is shown related to median 
time to death from relapse in days (with inter-quartile ranges in brackets). Significance is 
shown by p values, assessed by Kaplan-Meier analysis. Significant correlations are 
highlighted.
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Table 6a. Overall Survival (OS) and MAP Kinase expression divided according to 
median.
OS (years) P value
MAP Kinase (Nuclear) 
ASPC
Below Median 6.07 (5.06-7.08)
Above Median 6.65 (5.76-7.54) 0.60
MAP Kinase (Nuclear) 
AIPC
Below Median 6.04 (3.93-8.15)
Above Median 6.26 (3.98-8.54) 0.45
MAP Kinase (Cyto) 
ASPC
Below Median 7.68 (4.71-10.65)
Above Median 6.50 (5.50-7.50) 0.62
MAP Kinase (Cyto) 
AIPC
Below Median 6.04 (4.93-7.15)
Above Median 6.50 (3.48-9.52) 0.92
pMAP Kinase (Nuclear) 
ASPC
Below Median 6.07 (3.65-8.49)
Above Median 6.50 (5.26-7.74) 0.39
pMAP Kinase (Nuclear) 
AIPC
Below Median 4.92 (2.36-7.48)
Above Median 6.44 (5.19-7.69) 0.69
pMAP Kinase (Cyto) 
ASPC
Below Median 6.07 (5.14-7.00)
Above Median 6.50 (4.55-8.45 0.56
pMAP Kinase (Cyto) 
AIPC
Below Median 6.26 (3.94-8.58)
Above Median 5.82 (3.54-8.10) 0.83
Nuclear and cytoplasmic MAP Kinase expression (ASPC and AIPC), split into 2 subgroups - 
above and below median - is shown related to median overall survival in years (with inter­
quartile ranges in brackets). Significance is shown by p values, assessed by Kaplan-Meier 
analysis.
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Table 6b. O verall survival (OS) and M AP K inase expression d ivided according to
rising h istoscore w ith developm ent o f AIPC.
OS (years) P value
MAP Kinase (Nuclear) Non-Risers 6.89 (5.70-8.08)
Risers 3.37 (1.58-5.16) 0.0068
MAP Kinase Non-Risers 6.26 (5.47-7.05)
(Cyto)
Risers 6.89 (0-14.53) 0.98
pMAP Kinase (Nuclear) Non-Risers 6.57 (5.15-7.99)
Risers 6.07 (5.52-6.62) 0.98
pMAP Kinase (Cyto) Non-Risers 6.57 (5.49-7.65)
Risers 6.04 (3.21-8.87) 0.60
Nuclear and cytoplasmic MAP Kinase expression (ASPC and AIPC), divided into 2 
subgroups -  risers and non-risers with the development of AIPC - is shown related to median 
overall survival in years (with inter-quartile ranges in. brackets). Significance is shown by p 
values, assessed by Kaplan-Meier analysis. Significant correlations are highlighted.
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APPENDIX 5
Significant Correlations Between the Cytoplasmic and Nuclear Expression of MAP 
Kinase and its activated, phosphorylated form in ASPC and AIPC tumours.
Table 7a. Correlations between MAP Kinase protein histoscores in ASPC tumours.
MAP MAP Kinase pMAP pMAP Kinase
Kinase (Cytoplasm) Kinase (Cytoplasm)
(Nuclear) (Nuclear)
MAP Kinase 0.013 <0.001 0.014
(Nuclear) (0.321) (0.570) (0.334)
MAP Kinase 0.083 <0.001
(Cytoplasm) (0.238) (0.523)
pMAP <0.001
Kinase (0.703)
(Nuclear)
Table 7a shows correlations (p values) between the cytoplasmic and nuclear expression of 
MAP Kinase and its’ activated, phosphorylated form, in ASPC tumours. Significant 
correlations (p<0,05) are highlighted. P values were assessed by Spearman’s Rank 
Correlation Test, and correlation co-efficients are shown in brackets. 
pMAP Kinase, activated phosphorylated MAP Kinase
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Table 7b. Correlations between MAP Kinase protein histoscores in AIPC tumours. 
(Correlation co-efficients in brackets)
MAP MAP Kinase pMAP pMAP Kinase
Kinase (Cytoplasm) Kinase (Cytoplasm)
(Nuclear) (Nuclear)
MAP Kinase <0.001 0.24 0.39
(Nuclear) (0.613) (0.156) (0.113)
MAP Kinase 0.037 0.01
(Cytoplasm) (0.273) (0.335)
pMAP <0.001
Kinase (0.697)
(Nuclear)
Table 7b shows correlations (p values) between the cytoplasmic and nuclear expression of 
MAP Kinase and its’ activated, phosphorylated form, in AIPC tumours. Significant 
correlations (p<0.05) are highlighted. P values were assessed by Spearman’s Rank 
Correlation Test, and eorrelation co-efficients are shown in brackets. 
pMAP Kinase, activated phosphorylated MAP Kinase.
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